documents incorporated reference portions abbvie inc proxy statement incorporated reference part iii definitive proxy statement filed march part item business separation abbott laboratories abbvie incorporated delaware april january abbvie became independent company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott 's shareholders abbvie 's common stock began trading regularway ticker symbol abbv new york stock exchange january overview abbvie global researchbased biopharmaceutical company abbvie develops markets advanced therapies address world 's complex serious diseases abbvie 's products focused treating conditions chronic autoimmune diseases rheumatology gastroenterology dermatology oncology including blood cancers virology including hepatitis c hcv human immunodeficiency virus hiv neurological disorders parkinson 's disease metabolic diseases including thyroid disease complications associated cystic fibrosis well serious health conditions abbvie also pipeline promising new medicines including compounds indications clinical development across important medical specialties immunology virologyliver disease oncology neurological diseases women 's health may abbvie completed acquisition pharmacyclics inc biopharmaceutical company develops commercializes novel therapies people impacted cancer flagship asset imbruvica highly effective treatment hematologic malignancies approximately billion consisting cash consideration billion equity consideration billion segments abbvie operates one business segmentpharmaceutical products incorporated herein reference note entitled segment geographic area information notes consolidated financial statements included item financial statements supplementary data sales information related humira included item management 's discussion analysis financial condition results operationsresults operations products abbvie 's portfolio products includes broad line therapies address world 's complex serious diseases used throughout text report term abbvie refers abbvie inc delaware corporation abbvie inc consolidated subsidiaries context requires humira humira adalimumab biologic therapy administered subcutaneous injection approved treat following autoimmune diseases united states canada mexico collectively north america european union condition principal markets rheumatoid arthritis moderate severe north america european union psoriatic arthritis north america european union ankylosing spondylitis north america european union crohn 's disease moderate severe north america european union plaque psoriasis moderate severe north america european union juvenile idiopathic arthritis north america european union ulcerative colitis moderate severe united states european union axial spondyloarthropathy united states european union pediatric crohn 's disease severe united states european union hidradenitis suppurativa united states european union pediatric enthesitisrelated arthritis european union humira also approved markets including japan china brazil australia humira introduced market january humira abbvie 's largest product accounted approximately percent abbvie 's total net revenues united states composition matter compound patent covering adalimumab sold trademark humira expected expire december equivalent european union patent expected expire majority european union countries october addition united states noncomposition matter patents covering adalimumab expire earlier abbvie continues dedicate substantial research development efforts expanding indications humira including fields rheumatology gastroenterology pediatric ulcerative colitis ophthalmology uveitis regulatory application uveitis filed united states abbvie continues work humira formulation delivery enhancements improve convenience overall patient experience imbruvica imbruvica ibrutinib firstinclass oral oncedaily therapy inhibits protein called bruton 's tyrosine kinase btk imbruvica currently approved treatment patients chronic lymphocytic leukemia cll received least one prior therapy cll patients del p patients waldenstrm 's macroglobulinemia imbruvica also approved treatment patients mantle cell lymphoma mcl received least one prior therapy accelerated approval granted mcl indication based overall response rate continued approval indication may contingent upon verification clinical benefit confirmatory trials imbruvica one first medicines receive us food drug administration fda approval granted breakthrough therapy designation imbruvica one therapies receive three separate designations hcv products viekira pak ombitsavir paritaprevir ritonavir tablets dasabuvir tablets alloral shortcourse interferonfree therapy without ribavirin treatment adult patients genotype chronic hcv including compensated cirrhosis viekira pak approved fda december europe abbvie 's hcv treatment marketed viekirax exviera approved use patients genotype genotype hcv european commission granted marketing authorization treatment january july fda approved abbvie 's technivie ombitasvir paritaprevir ritonavir use combination ribavirin treatment adults genotype hcv infection united states additional virology products abbvie 's additional virology products include kaletra norvir treatment hiv infection synagis prevention respiratory syncytial virus rsv infection high risk infants kaletra kaletra lopinavirritonavir also marketed aluvia emerging markets prescription antihiv medicine contains two protease inhibitors lopinavir ritonavir kaletra used antihiv medications treatment maintains viral suppression people hiv norvir norvir ritonavir protease inhibitor indicated combination antiretroviral agents treatment hiv infection synagis synagis palivizumab product marketed abbvie outside united states protects atrisk infants severe respiratory disease caused rsv metabolicshormones products metabolic hormone products target number conditions including testosterone deficiency exocrine pancreatic insufficiency hypothyroidism products include androgel androgel testosterone gel testosterone replacement therapy males diagnosed symptomatic low testosterone available two strengths percent percent creon creon pancrelipase pancreatic enzyme therapy exocrine pancreatic insufficiency condition occurs patients cystic fibrosis chronic pancreatitis several conditions synthroid synthroid levothyroxine sodium tablets usp used treatment hypothyroidism abbvie rights sell androgel creon synthroid united states endocrinology products lupron levprolide acetate also marketed lucrin lupron depot product palliative treatment advanced prostate cancer treatment endometriosis central precocious puberty preoperative treatment patients anemia caused uterine fibroids lupron approved daily subcutaneous injection onemonth threemonth fourmonth sixmonth intramuscular injection products abbvie 's products include following duopa duodopa carbidopa levodopa abbvie 's levodopacarbidopa intestinal gel treatment advanced parkinson 's disease marketed duopa united states duodopa outside united states anesthesia products sevoflurane sold trademarks ultane sevorane anesthesia product abbvie sells worldwide human use dyslipidemia products abbvie 's dyslipidemia products tricor fenofibrate trilipix fenofibric acid niaspan niacin extended release address range metabolic conditions characterized high cholesterol andor high triglycerides zemplar zemplar paricalcitol product sold worldwide treatment secondary hyperparathyroidism associated stage chronic kidney disease ckd research development activities abbvie numerous compounds clinical development including potential treatments complex lifethreatening diseases abbvie 's ability discover develop new compounds enhanced company 's use integrated discovery development project teams include chemists biologists physicians pharmacologists work compounds team research development process generally begins discovery research focuses identification molecule desired effect given disease preclinical testing identified compound proves successful compound moves clinical development generally includes following phases phase involves first human tests small number healthy volunteers patients assess safety tolerability potential dosing phase tests drug 's efficacy disease relatively small group patients phase tests drug demonstrates favorable results earlier phases significantly larger patient population demonstrate efficacy safety based regulatory criteria clinical trials development phases provide data required prepare submit new drug application nda biological license application bla submission regulatory approval fda similar government agencies outside united states specific requirements eg scope clinical trials obtaining regulatory approval vary across different countries geographic regions research development process discovery new drug launch typically takes years even longer research development new pharmaceutical products significant amount inherent uncertainty guarantee molecule receive regulatory approval required launch new drug indication addition development new products new formulations research development projects also may include phase trials sometimes called postmarketing studies projects clinical trials designed conducted collect additional data regarding among parameters benefits risks approved drug abbvie spent approximately billion billion billion research discover develop new products indications processes improve existing products processes expenses consisted primarily salaries related expenses personnel license fees consulting payments contract research clinical drug supply manufacturing costs laboratory equipment facilities clinical trial costs collaboration fees expenses intellectual property protection regulatory exclusivity generally upon approval products may entitled certain kinds exclusivity applicable intellectual property regulatory regimes abbvie seeks patent protection available significant markets andor countries product development united states expiration date patents filed june years filing date given patents relating pharmaceutical products often obtained early development process given amount time needed complete clinical trials development activities required regulatory approval length time product launch patent expiration significantly less years drug price competition patent term restoration act commonly known hatchwaxman act permits patent holder seek patent extension commonly called patent term restoration patents products processes making product regulated federal food drug cosmetic act length patent extension roughly based percent period time filing investigational new drug application compound submission nda compound plus percent time period nda submission regulatory approval extension however exceed five years patent term remaining regulatory approval exceed years pharmaceutical products may entitled forms legal regulatory exclusivity upon approval scope length requirements exclusivities vary united states jurisdictions united states fda approves drug product contains active ingredient previously approved product typically entitled five years nonpatent regulatory exclusivity products may entitled three years exclusivity approval based fda 's reliance new clinical studies essential approval submitted nda applicant nda applicant studies product use children fda may grant pediatric exclusivity extends days longest existing exclusivity patent regulatory related product products either used treat conditions afflict relatively small population reasonable expectation research development costs recovered fda may designate pharmaceutical orphan drug grant seven years market exclusivity applicable laws regulations dictate scope exclusivity product entitled upon approval particular country certain instances regulatory exclusivity may protect product patent protection longer available period time excess patent protection possible estimate product development total period scope exclusivity may become entitled regulatory approval obtained however given length time required complete clinical development pharmaceutical product minimum maximum periods exclusivity might achieved individual case would expected exceed three years respectively estimates consider factors difficulty recreating manufacturing process particular product proprietary knowledge may delay introduction generic followon product expiration applicable patent regulatory exclusivity periods biologics may entitled exclusivity biologics price competition innovation act passed march title vii patient protection affordable care act law provides pathway approval biosimilars following expiration years exclusivity innovator biologic potential additional dayextension term conducting pediatric studies biologics also eligible orphan drug exclusivity discussed law also includes extensive process innovator biologic biosimilar manufacturer litigate patent infringement validity enforceability prior approval biosimilar european union also created pathway approval biosimilars published guidelines approval certain biosimilar products complex nature biologics biosimilar products led greater regulatory scrutiny rigorous requirements approval followon biosimilar products small molecule generic pharmaceutical products european union also reduced effect biosimilars sales innovator biologic compared sales erosion caused generic versions small molecule pharmaceutical products abbvie owns licensed rights substantial number patents patent applications abbvie licenses owns patent portfolio thousands patent families includes united states patent applications andor issued patents may also contain nonunited states counterparts patents applications patents applications including various patents expire period late aggregate believed material importance operation abbvie 's business however abbvie believes single patent license trademark related group patents licenses trademarks except related adalimumab sold trademark humira material relation company 's business whole united states composition matter compound patent covering adalimumab expected expire december equivalent european union patent expected expire majority european union countries october united states noncomposition matter patents covering adalimumab expire earlier addition following patents licenses trademarks significant related ibrutinib sold trademark imbruvica related ombitasvirparitaprevirritonavir dasabuvir sold trademarks viekira pak viekirax exviera holkira pak related testosterone sold trademark androgel united states composition matter patent covering ibrutinib expected expire united states composition matter patents covering ombitasvir paritaprevir dasabuvir expected expire respectively abbvie may rely circumstances trade secrets protect technology however trade secrets difficult protect abbvie seeks protect technology product candidates part confidentiality agreements employees consultants advisors contractors collaborators agreements may breached abbvie may adequate remedies breach addition abbvie 's trade secrets may otherwise become known independently discovered competitors extent abbvie 's employees consultants advisors contractors collaborators use intellectual property owned others work company disputes may arise rights related resulting knowhow inventions marketing sales distribution capabilities abbvie utilizes combination dedicated commercial resources regional commercial resources distributorships market sell distribute products worldwide abbvie directs primary marketing efforts toward securing prescription recommendation brand products physicians key opinion leaders health care providers managed care providers example health maintenance organizations pharmacy benefit managers hospitals state federal government agencies example united states department veterans affairs united states department defense also important customers abbvie also markets directly consumers although united states company 's products must sold pursuant prescription outside united states abbvie focuses marketing efforts key opinion leaders payors physicians country regulatory bodies abbvie also provides patient support programs closely related products abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses although abbvie 's business significant seasonality abbvie 's product revenues may affected end customer retail buying patterns fluctuations wholesaler inventory levels factors united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly pharmacies patients three wholesale distributors mckesson corporation cardinal health inc amerisourcebergen corporation accounted substantially abbvie 's sales united states individual wholesaler accounted greater percent abbvie 's gross revenues united states outside united states sales made either directly customers distributors depending market served wholesalers purchase product abbvie standard terms conditions sale certain products comarketed copromoted companies abbvie single customer customer lost would material adverse effect company 's business material portion abbvie 's business subject renegotiation profits termination contracts election government orders generally filled current basis order backlog material abbvie 's business third party agreements abbvie agreements third parties process development analytical services manufacturing certain products abbvie procures certain products services limited number suppliers cases single supply source example filling packaging humira syringes sold outside united states puerto rico performed single supplier two different facilities abbvie currently believe agreement material abbvie 's business substantially risk without access facilities abbvie maintains significant inventory humira syringes reduce risk supply disruption syringefilling packaging facility united states approved supply syringes primary markets outside united states puerto rico addition abbvie agreements third parties active pharmaceutical ingredient product manufacturing formulation development services fill finish packaging services transportation distribution logistics services certain products abbvie believe manufacturing related agreements material abbvie 's business substantially dependent individual agreement cases abbvie maintains alternate supply relationships utilize without undue disruption manufacturing processes third party fails perform contractual obligations abbvie also maintains sufficient inventory product minimize impact supply disruption abbvie also party certain collaborations arrangements discussed note licensing acquisitions arrangements licensing acquisitions activity notes consolidated financial statements included item financial statements supplementary data certain agreements abbott discussed item management 's discussion analysis financial condition results operationstransition abbott cost operate independent company sources availability raw materials abbvie purchases ordinary course business raw materials supplies essential operations numerous suppliers around world addition certain medical devices components necessary manufacture abbvie products provided unaffiliated third party suppliers abbvie experienced recent significant availability problems supply shortages forecasted sales environmental matters abbvie believes operations comply material respects applicable laws regulations concerning environmental protection regulations federal state environmental laws impose stringent limitations emissions discharges environment various manufacturing operations abbvie 's capital operating expenditures pollution control approximately million million respectively capital operating expenditures pollution control estimated approximately million million respectively abbott identified one many potentially responsible parties investigations andor remediations several locations united states including puerto rico comprehensive environmental response compensation liability act commonly known superfund locations transferred abbvie connection separation distribution abbvie become party investigations remediations abbott also engaged remediation several sites transferred abbvie connection separation distribution cooperation environmental protection agency similar agencies feasible predict certainty final costs related investigations remediation activities abbvie believes costs together expenditures maintain compliance applicable laws regulations concerning environmental protection material adverse effect company 's financial position cash flows results operations competition markets abbvie 's products highly competitive abbvie competes researchbased pharmaceuticals biotechnology companies discover manufacture market sell proprietary pharmaceutical products biologics example humira competes number antitnf products approved number disease states abbvie 's virology products compete protease inhibitors antihiv treatments search technological innovations pharmaceutical products significant aspect competition introduction new products competitors changes medical practices procedures result product obsolescence price also competitive factor addition substitution generic pharmaceutical products branded pharmaceutical products creates competitive pressures abbvie 's products patent protection biosimilars competition abbvie 's biologic products affected approval followon biologics also known biosimilars biologics added major therapeutic options treatment many diseases including therapies unavailable inadequate advent biologics also raised complex regulatory issues significant pharmacoeconomic concerns cost developing producing biologic therapies typically dramatically higher conventional small molecule medications many expensive biologic medications used ongoing treatment chronic diseases rheumatoid arthritis inflammatory bowel disease treatment previously untreatable cancer significant investments biologics infrastructure manufacturing necessary produce biologic products significant investments marketing distribution sales organization activities may limit number biosimilar competitors united states fda regulates biologics federal food drug cosmetic act public health service act implementing regulations enactment federal health care reform legislation march provided pathway approval biosimilars public health service act approval process science behind biosimilars complex approval process science behind generic followon versions small molecule products added complexity due steps needed ensure safety efficacy biosimilars highly similar original biologic humira ultimate approval fda dependent upon many factors including showing biosimilar highly similar original product clinically meaningful differences original product terms safety purity potency vitro characterization types data could ordinarily required application show similarity may include analytical data studies demonstrate chemical similarity animal studies including toxicity studies clinical studies law also requires biosimilar must condition use approved original biologic manufacturing facility meets standards necessary assure biosimilar safe pure potent furthermore law provides biosimilar product determined interchangeable considered substitutable original biologic product without intervention health care provider prescribed original biologic product prove biosimilar product interchangeable applicant must demonstrate product expected produce clinical results original biologic product given patient product administered patient safety risks potential diminished efficacy alternating switching use interchangeable biosimilar biologic product original biologic product greater risk using original biologic product without switching law beginning interpreted implemented fda result ultimate impact implementation meaning likely subject substantial uncertainty years come european union pathway approval biosimilars existed since products come market date mixed impact market share incumbent products significant variation product competitive products although number competitive biologic branded products approved since humira first introduced gained modest share worldwide market abbvie continue face competitive pressure biologics orally administered products regulationdiscovery clinical development united states securing approval market new pharmaceutical product united states requires substantial effort financial resources takes several years complete applicant must complete preclinical tests submit protocols fda commencing clinical trials clinical trials intended establish safety efficacy pharmaceutical product typically conducted three sequential phases although phases may overlap combined required clinical testing successful results submitted fda form nda bla requesting approval market product one indications fda reviews nda bla determine whether product safe effective intended use whether manufacturing compliant current good manufacturing practices cgmp even nda bla receives approval applicant must comply postapproval requirements example holders approval must report adverse reactions provide updated safety efficacy information comply requirements concerning advertising promotional materials activities also quality control manufacturing procedures must continue conform cgmp approval certain changes manufacturing procedures finished product must included nda bla approved fda fda periodically inspects manufacturing facilities assess compliance cgmp imposes extensive procedural record keeping requirements addition condition approval fda may require postmarketing testing surveillance assess monitor product 's safety efficacy commercialization may require additional clinical trials patient registries additional work chemistry manufacturing controls postapproval regulatory obligations cost complying obligations could expand future outside united states abbvie subject similar regulatory requirements outside united states abbvie must obtain approval clinical trial application product applicable regulatory authorities commence clinical trials marketing product approval requirements process country vary time required obtain approval may longer shorter required fda approval united states example abbvie may submit marketing authorizations european union either centralized decentralized procedure centralized procedure mandatory approval biotechnology products many pharmaceutical products provides single marketing authorization valid european union member states centralized procedure single marketing authorization application submitted european medicines agency agency evaluates application makes recommendation european commission makes final determination whether approve application decentralized procedure provides mutual recognition individual national approval decisions available products subject centralized procedure japan applications approval new product made pharmaceutical medical devices agency pmda bridging studies demonstrate nonjapanese clinical data applies japanese patients may required completing comprehensive review pmda reports ministry health labour welfare approves denies application regulatory process many emerging markets continues evolve many emerging markets including asia generally require regulatory approval obtained large developed market united states europe country begin complete regulatory review process countries also require local clinical studies conducted order obtain regulatory approval country requirements governing conduct clinical trials product licensing also vary addition postapproval regulatory obligations adverse event reporting cgmp compliance generally apply may vary country example marketing authorization granted european union periodic safety reports must submitted pharmacovigilance measures may required risk management plans regulationcommercialization distribution manufacturing manufacture marketing sale promotion distribution abbvie 's products subject comprehensive government regulation government regulation various national regional federal state local agencies united states countries addresses among matters inspection controls research laboratory procedures clinical investigations product approvals manufacturing labeling packaging marketing promotion pricing reimbursement sampling distribution quality control postmarketing surveillance record keeping storage disposal practices abbvie 's operations also affected trade regulations many countries limit import raw materials finished products laws regulations seek prevent corruption bribery marketplace including united states foreign corrupt practices act united kingdom bribery act provide guidance corporate interactions government officials require safeguards protection personal data addition abbvie subject laws regulations pertaining health care fraud abuse including state federal antikickback false claims laws united states prescription drug manufacturers abbvie also subject taxes well application product user establishment fees compliance laws regulations costly materially affects abbvie 's business among effects health care regulations substantially increase time difficulty costs incurred obtaining maintaining approval market newly developed existing products abbvie expects compliance regulations continue require significant technical expertise capital investment ensure compliance failure comply delay release new product result regulatory enforcement actions seizure recall product suspension revocation authority necessary product 's production sale civil criminal sanctions including fines penalties addition regulatory initiatives abbvie 's business affected ongoing studies utilization safety efficacy outcomes health care products components regularly conducted industry participants government agencies others studies call question utilization safety efficacy previously marketed products cases studies resulted may future result discontinuance limitations marketing products domestically worldwide may give rise claims damages persons believe injured result use access human health care products continues subject investigation action governmental agencies legislative bodies private organizations united states countries major focus cost containment efforts reduce health care costs also made private sector notably health care payors providers instituted various cost reduction containment measures abbvie expects insurers providers continue attempts reduce cost health care products outside united states many countries control price health care products directly indirectly reimbursement payment pricing coverage limitations compulsory licensing budgetary pressures united states countries may also heighten scope severity pricing pressures abbvie 's products foreseeable future united states specifically us federal laws require pharmaceutical manufacturers pay certain statutorilyprescribed rebates state medicaid programs prescription drugs reimbursed state medicaid plans efforts states seek additional rebates affect abbvie 's business similarly veterans health care act prerequisite participation medicaid federal health care programs requires manufacturers extend additional discounts pharmaceutical products various federal agencies including united states department veterans affairs department defense public health service entities institutions addition recent legislative changes would require similarly discounted prices offered tricare program beneficiaries veterans health care act also established b drug discount program requires pharmaceutical manufacturers provide products reduced prices various designated health care entities facilities united states states also generic substitution legislation requiring permitting dispensing pharmacist substitute different manufacturer 's generic version pharmaceutical product one prescribed addition federal government follows diagnosisrelated group drg payment system certain institutional services provided medicare medicaid implemented prospective payment system pps services delivered hospital outpatient nursing home home health settings drg pps entitle health care facility fixed reimbursement based diagnosis andor procedure rather actual costs incurred patient treatment thereby increasing incentive facility limit control expenditures many health care products medicare reimburses part b drugs based average sales price plus certain percentage account physician administration costs recently reduced hospital outpatient setting medicare enters contracts private plans negotiate prices patientadministered medicine delivered part march congress enacted patient protection affordable care act health care education reconciliation act together affordable care act affordable care act abbvie pays fee related pharmaceuticals sales government programs also abbvie began providing discount percent branded prescription drugs sold patients fall medicare part coverage gap donut hole affordable care act also includes provisions known physician payments sunshine act require manufacturers drugs biologics covered medicare medicaid starting record transfers value physicians teaching hospitals report data beginning centers medicare medicaid services subsequent public disclosure similar reporting requirements also enacted state level united states increasing number countries worldwide either adopted considering similar laws requiring disclosure interactions health care professionals failure report appropriate data may result civil criminal fines andor penalties abbvie expects debate continue government levels worldwide marketing availability method delivery payment health care products services abbvie believes future legislation regulation markets serves could affect access health care products services increase rebates reduce prices rate price increases health care products services change health care delivery systems create new fees obligations pharmaceuticals industry require additional reporting disclosure possible predict extent abbvie health care industry general might affected matters discussed abbvie subject corporate integrity agreement cia entered abbott may requires enhancements abbvie 's compliance program contains reporting obligations including disclosure financial payments doctors abbvie fails comply cia office inspector general united states department health human services may impose monetary penalties exclude abbvie federal health care programs including medicare medicaid european union european union adopted directives legislation governing labeling advertising distribution supply pharmacovigilance marketing pharmaceutical products legislation provides mandatory standards throughout european union permits member states supplement standards additional regulations european governments also regulate pharmaceutical product prices control national health care systems fund large part cost products consumers result patients unlikely use pharmaceutical product reimbursed government many european countries government either regulates pricing new product launch subsequent launch direct price controls reference pricing recent years many countries also imposed new additional cost containment measures pharmaceutical products differences national pricing regimes create price differentials within european union lead significant parallel trade pharmaceutical products governments also promote generic substitution mandating permitting pharmacist substitute different manufacturer 's generic version pharmaceutical product one prescribed permitting mandating health care professionals prescribe generic versions certain circumstances addition governments use reimbursement lists limit pharmaceutical products eligible reimbursement national health care systems japan japan national health insurance system maintains drug price list specifying pharmaceutical products eligible reimbursement ministry health labour welfare sets prices products list government generally introduces price cut rounds every year also mandates price decreases specific products new products judged innovative useful indicated pediatric use target orphan small population diseases however may eligible pricing premium government also promoted use generics available emerging markets many emerging markets take steps reduce pharmaceutical product prices cases direct price controls others promotion generic alternatives branded pharmaceuticals since abbvie markets products worldwide certain products local nature variations product lines must also meet local regulatory requirements certain additional risks inherent conducting business outside united states including price currency exchange controls changes currency exchange rates limitations participation local enterprises expropriation nationalization governmental action employees abbvie employed approximately persons january outside united states abbvie 's employees represented unions works councils abbvie believes good relations employees internet information copies abbvie 's annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act available free charge abbvie 's investor relations website wwwabbvieinvestorcom soon reasonably practicable abbvie electronically files material furnishes securities exchange commission sec abbvie 's corporate governance guidelines outline directorship qualifications code business conduct charters abbvie 's audit committee compensation committee nominations governance committee public policy committee available abbvie 's investor relations website wwwabbvieinvestorcom item risk factors carefully consider following risks information evaluating abbvie abbvie 's common stock following risks could materially adversely affect abbvie 's results operations financial condition cash flows risk factors generally separated three groups risks related abbvie 's business risks related abbvie 's separation abbott risks related abbvie 's common stock based information currently known abbvie believes following information identifies significant risk factors affecting categories risks however risks uncertainties abbvie faces limited set forth risk factors described may order importance probability occurrence additional risks uncertainties presently known abbvie abbvie currently believes immaterial may also adversely affect business addition past financial performance may reliable indicator future performance historical trends used anticipate results trends future periods following risks uncertainties develops actual events events could material adverse effect abbvie 's business results operations financial condition cash flows case trading price abbvie 's common stock could decline risks related abbvie 's business expiration loss patent protection licenses may adversely affect abbvie 's future revenues operating earnings abbvie relies patent trademark intellectual property protection discovery development manufacturing sale products particular patent protection aggregate important abbvie 's marketing pharmaceutical products united states major markets outside united states patents covering abbvie products normally provide market exclusivity important profitability many abbvie 's products patents certain products expire abbvie could face competition lower priced generic products expiration loss patent protection product typically followed promptly substitutes may significantly reduce sales product short amount time abbvie 's competitive position compromised generics otherwise could material adverse effect abbvie 's business results operations addition proposals emerge time time legislation encourage early rapid approval generic drugs proposals enacted law could increase impact generic competition abbvie 's principal patents trademarks described greater detail item businessintellectual property protection regulatory exclusivity item management 's discussion analysis financial condition results operationsresults operations litigation regarding patents described item legal proceedings united states composition matter patent humira abbvie 's largest product worldwide net revenues approximately billion expected expire december equivalent european union patent expected expire majority european union countries october humira biologic biologics readily substituted uncertain impact loss patent protection would sales humira abbvie 's major products could lose patent protection earlier expected could adversely affect abbvie 's future revenues operating earnings third parties government authorities may challenge seek invalidate circumvent abbvie 's patents patent applications example manufacturers generic pharmaceutical products file may continue file abbreviated new drug applications fda seeking market generic forms abbvie 's products prior expiration relevant patents owned licensed abbvie asserting patents invalid unenforceable andor infringed addition petitioners filed may continue file challenges validity abbvie patents leahysmith america invents act created inter partes review post grant review procedures challenging patent validity administrative proceedings united states patent trademark office although challenges abbvie 's intellectual property come businesses governments may also challenge intellectual property rights example court decisions potential legislation relating patents legislation regarding biosimilars regulatory initiatives may result erosion intellectual property protection addition certain governments outside united states indicated compulsory licenses patents may sought domestic policies basis national emergencies hivaids triggered compulsory licenses could diminish eliminate sales profits jurisdictions negatively affect abbvie 's results operations abbvie normally responds challenges vigorously defending patents including filing patent infringement lawsuits patent litigation administrative proceedings challenges abbvie 's patents costly unpredictable may deprive abbvie market exclusivity patented product extent abbvie 's intellectual property successfully challenged circumvented extent intellectual property allow abbvie compete effectively abbvie 's business suffer extent countries enforce abbvie 's intellectual property rights require compulsory licensing abbvie 's intellectual property abbvie 's future revenues operating earnings reduced third party 's intellectual property may prevent abbvie selling products material adverse effect abbvie 's future profitability financial condition third parties may claim abbvie product infringes upon intellectual property resolving intellectual property infringement claim costly time consuming may require abbvie enter license agreements abbvie guarantee would able obtain license agreements commercially reasonable terms successful claim patent intellectual property infringement could subject abbvie significant damages injunction preventing manufacture sale use affected abbvie product products events could material adverse effect abbvie 's profitability financial condition significant event adversely affects humira revenues could material negative impact abbvie 's results operations cash flows humira accounted approximately percent abbvie 's total net revenues significant event adversely affects humira 's revenues could material adverse impact abbvie 's results operations cash flows events could include loss patent protection humira approval biosimilars humira discovery previously unknown side effects impaired efficacy increased competition introduction new effective less expensive treatments discontinuation removal market humira reason abbvie 's research development efforts may succeed developing marketing commercially successful products technologies may cause revenues profitability decline remain competitive abbvie must continue launch new products new indications andor brand extensions existing products launches must generate revenue sufficient cover substantial research development costs replace revenues profitable products lost displaced competing products therapies failure would material adverse effect abbvie 's revenue profitability accordingly abbvie commits substantial effort funds resources research development must make ongoing substantial expenditures without assurance efforts commercially successful high rate failure biopharmaceutical industry inherent research development new products failure occur point research development process including significant funds invested products appear promising development may fail reach market numerous reasons including failure demonstrate effectiveness safety concerns superior safety efficacy competing therapies failure achieve positive clinical preclinical outcomes beyond current standards care inability obtain necessary regulatory approvals delays approval new products new indications limited scope approved uses excessive costs manufacture failure obtain maintain intellectual property rights infringement intellectual property rights others decisions research studies made early development process pharmaceutical product candidate affect marketing strategy candidate receives approval detailed studies may demonstrate additional benefits help marketing also consume time resources may delay submitting pharmaceutical product candidate approval abbvie guarantee proper balance speed testing made respect pharmaceutical product candidate decisions area would adversely affect abbvie 's future results operations even abbvie successfully develops markets new products enhancements existing products may quickly rendered obsolete changing clinical preferences changing industry standards competitors ' innovations abbvie 's innovations may accepted quickly marketplace existing clinical practices uncertainty thirdparty reimbursement abbvie state certainty whether products development launched whether able develop license otherwise acquire compounds products whether products commercially successful failure launch successful new products new indications existing products may cause abbvie 's products become obsolete causing abbvie 's revenues operating results suffer portion abbvie 's nearterm pharmaceutical pipeline relies collaborations third parties may adversely affect development sale products abbvie depends alliances pharmaceutical biotechnology companies portion products nearterm pharmaceutical pipeline example abbvie collaborating biogen develop treatment relapsing remitting form multiple sclerosis also collaborating roche holding ag discover develop commercialize nextgeneration bcl inhibitor abt venetoclax patients relapsedrefractory chronic lymphocytic leukemia failures parties meet contractual regulatory obligations abbvie disruption relationships abbvie third parties could adverse effect abbvie 's pharmaceutical pipeline business addition abbvie 's collaborative relationships research development extend many years may give rise disputes regarding relative rights obligations revenues abbvie collaboration partners including ownership intellectual property associated rights obligations could result loss intellectual property rights protection delay development sale potential pharmaceutical products lead lengthy expensive litigation administrative proceedings arbitration biologics carry unique risks uncertainties could negative impact future results operations successful discovery development manufacturing sale biologics long expensive uncertain process unique risks uncertainties biologics example access supply necessary biological materials cell lines may limited governmental regulations restrict access regulate transport use materials addition development manufacturing sale biologics subject regulations often complex extensive regulations applicable pharmaceutical products manufacturing biologics especially large quantities often complex may require use innovative technologies manufacturing also requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures biologics also frequently costly manufacture production inputs derived living animal plant material biologics made synthetically failure successfully discover develop manufacture sell biologicsincluding humiracould adversely impact abbvie 's business results operations abbvie 's biologic products may become subject competition biosimilars biologics price competition innovation act passed march title vii patient protection affordable care act law created framework approval biosimilars united states could allow competitors reference data biologic products already approved europe european commission granted marketing authorizations several biosimilars pursuant set general product classspecific guidelines biosimilar approvals issued past years addition companies developing biosimilars countries could compete abbvie 's biologic products example amgen submitted marketing authorization application european medicines agency biosimilar humira united states fda accepted review amgen 's application humira biosimilar competitors able obtain marketing approval biosimilars referencing abbvie 's biologic products abbvie 's products may become subject competition biosimilars attendant competitive pressure consequences expiration successful challenge abbvie 's applicable patent rights could also trigger competition products assuming relevant exclusivity period expired result abbvie could face litigation administrative proceedings respect validity andor scope patents relating biologic products new products technological advances abbvie 's competitors may negatively affect abbvie 's results operations abbvie competes researchbased pharmaceutical biotechnology companies discover manufacture market sell proprietary pharmaceutical products biologics example humira competes number antitnf products approved number disease states abbvie 's virology products compete protease inhibitors antihiv treatments competitors may introduce new products develop technological advances compete abbvie 's products therapeutic areas immunology virologyliver disease oncology dyslipidemia neuroscience abbvie predict certainty timing impact introduction competitors new products technological advances competing products may safer effective effectively marketed sold lower prices superior performance features abbvie 's products could negatively impact abbvie 's business results operations manufacture many abbvie 's products highly exacting complex process abbvie one suppliers encounters problems manufacturing abbvie 's products abbvie 's business could suffer manufacture many abbvie 's products highly exacting complex process due part strict regulatory requirements problems may arise manufacturing variety reasons including equipment malfunction failure follow specific protocols procedures problems raw materials delays related construction new facilities expansion existing facilities including intended support future demand abbvie 's products changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could inhibit continuous supply manmade natural disasters environmental factors problems arise production batch product batch product may discarded abbvie may experience product shortages incur added expenses could among things lead increased costs lost revenue damage customer relations time expense spent investigating cause depending cause similar losses respect batches products problems discovered product released market recall product liability costs may also incurred abbvie uses number products pharmaceutical biologic manufacturing processes sourced single suppliers interruption supply products could adversely affect abbvie 's business results operations abbvie uses number products pharmaceutical biologic manufacturing processes sourced single suppliers failure singlesource suppliers fulfill contractual obligations timely manner result regulatory noncompliance physical disruption manufacturing site may impair abbvie 's ability deliver products customers timely competitive basis could adversely affect abbvie 's business results operations finding alternative supplier could take significant amount time involve significant expense due nature products need obtain regulatory approvals abbvie guarantee able reach agreement alternative providers regulatory authorities would approve abbvie 's use alternatives abbvie however carry business interruption insurance provides degree protection case failure singlesource supplier significant safety efficacy issues could arise abbvie 's products could material adverse effect abbvie 's revenues financial condition pharmaceutical products receive regulatory approval based data obtained controlled clinical trials limited duration following regulatory approval products used longer periods time many patients investigators may also conduct additional perhaps extensive studies new safety efficacy issues reported new scientific information becomes available including results postmarketing phase trials governments change standards regarding safety efficacy labeling abbvie may required amend conditions use product example abbvie may voluntarily provide required provide updated information product 's label narrow approved indication either could reduce product 's market acceptance safety efficacy issues abbvie product arise sales product could halted abbvie regulatory authorities safety efficacy issues affecting suppliers ' competitors ' products also may reduce market acceptance abbvie 's products new data abbvie 's products products similar products could negatively impact demand abbvie 's products due real perceived safety issues uncertainty regarding efficacy cases could result product withdrawal furthermore new data information including information product misuse may lead government agencies professional societies practice management groups organizations involved various diseases publish guidelines recommendations related use abbvie 's products use related therapies place restrictions sales guidelines recommendations may lead lower sales abbvie 's products abbvie subject product liability claims lawsuits may adversely affect business results operations ordinary course business abbvie subject product liability claims lawsuits alleging abbvie 's products products companies promotes resulted could result unsafe condition injury patients product liability claims lawsuits safety alerts product recalls regardless ultimate outcome may material adverse effect abbvie 's business results operations reputation ability attract retain customers consequences may also include additional costs decrease market share product question lower income exposure claims product liability losses selfinsured abbvie subject costcontainment efforts pricing pressures could cause reduction future revenues operating earnings changes terms rebate chargeback programs common pharmaceuticals industry could material adverse effect abbvie 's operations costcontainment efforts governments private organizations described greater detail item businessregulation commercialization distribution manufacturing extent cost containment efforts offset greater demand increased patient access health care factors abbvie 's future revenues operating earnings reduced united states european union countries abbvie 's business experienced downward pressure product pricing pressure could increase future united states practices managed care groups institutional governmental purchasers united states federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act contribute pricing pressures potential continuing changes health care system united states increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result additional pricing pressures numerous major markets worldwide government plays significant role funding health care services determining pricing reimbursement pharmaceutical products consequently markets abbvie subject government decisionmaking budgetary actions respect products particular many european countries ongoing governmentmandated price reductions many pharmaceutical products abbvie anticipates continuing pricing pressures europe differences countries pricing regulations could lead thirdparty crossborder trading abbvie 's products results reduction future revenues operating earnings rebates related government programs feeforservice medicaid medicaid managed care programs arise laws regulations abbvie predict additional government initiatives contain health care costs factors could lead new modified regulatory requirements include higher incremental rebates discounts rebate discount programs arise contractual agreements private payers various factors including market factors ability private payers control patient access products may provide payers leverage negotiate higher additional rebates discounts could material adverse effect abbvie 's operations abbvie subject numerous governmental regulations costly comply regulations develop compliant products processes abbvie 's products subject rigorous regulation numerous international supranational federal state authorities described item businessregulationdiscovery clinical development process obtaining regulatory approvals market pharmaceutical product costly time consuming approvals might granted future products additional indications uses existing products timely basis delays receipt failure obtain approvals future products new indications uses could result delayed realization product revenues reduction revenues substantial additional costs addition abbvie guarantee remain compliant applicable regulatory requirements approval obtained product requirements include among things regulations regarding manufacturing practices product labeling advertising post marketing reporting including adverse event reports field alerts due manufacturing quality concerns abbvie must incur expense spend time effort ensure compliance complex regulations possible regulatory actions could result substantial modifications abbvie 's business practices operations refunds recalls seizures abbvie 's products total partial shutdown production one abbvie 's suppliers ' facilities abbvie supplier remedies alleged violation inability obtain future approvals withdrawals suspensions current products market events could disrupt abbvie 's business material adverse effect business results operations laws regulations affecting government benefit programs could impose new obligations abbvie require change business practices restrict operations future health care industry subject various federal state international laws regulations pertaining government benefit programs reimbursement rebates price reporting regulation health care fraud abuse united states laws include antikickback false claims laws medicaid rebate statute veterans health care act individual state laws relating pricing sales marketing practices violations laws may punishable criminal andor civil sanctions including instances substantial fines imprisonment exclusion participation federal state health care programs including medicare medicaid veterans administration health programs laws regulations broad scope subject change evolving interpretations could require abbvie incur substantial costs associated compliance alter one sales marketing practices addition violations laws allegations violations could disrupt abbvie 's business result material adverse effect business results operations abbvie could subject increased monetary penalties andor sanctions including exclusion federal health care programs fails comply terms may resolution department justice 's investigation sales marketing activities depakote may abbott settled united states federal state investigations sales marketing activities depakote pleading guilty misdemeanor violation food drug cosmetic act agreeing pay approximately million criminal fines forfeitures approximately million resolve civil claims submitting term probation term probation ended january upon abbvie satisfying probation conditions however abbvie violates remaining terms plea agreement may face additional monetary sanctions remedies court deems appropriate addition abbott entered fiveyear cia office inspector general united states department health human services oig effective date cia october obligations cia transferred become fully binding abbvie cia requires enhancements abbvie 's compliance program fulfillment reporting monitoring obligations management certifications resolutions abbvie 's board directors among requirements compliance requirements settlement impose additional costs burdens abbvie including form employee training third party reviews compliance monitoring reporting obligations management attention abbvie fails comply cia oig may impose monetary penalties exclude abbvie federal health care programs including medicare medicaid abbvie abbott may subject third party claims shareholder lawsuits connection settlement abbvie may required indemnify portion abbott 's costs international nature abbvie 's business subjects additional business risks may cause revenue profitability decline abbvie 's business subject risks associated business internationally including emerging markets net revenues outside united states make approximately percent abbvie 's total net revenues risks associated abbvie 's operations outside united states include fluctuations currency exchange rates changes medical reimbursement policies programs multiple legal regulatory requirements subject change could restrict abbvie 's ability manufacture market sell products differing local product preferences product requirements trade protection measures import export licensing requirements difficulty establishing staffing managing operations differing labor regulations potentially negative consequences changes interpretations tax laws political economic instability including sovereign debt issues price currency exchange controls limitations participation local enterprises expropriation nationalization governmental action inflation recession fluctuations interest rates potential deterioration economic position credit quality certain nonus countries including europe latin america potential penalties adverse consequences violations anticorruption antibribery similar laws regulations including united states foreign corrupt practices act united kingdom bribery act events contemplated risks may individually aggregate material adverse effect abbvie 's revenues profitability abbvie 's ability realize anticipated benefits merger pharmacyclics depend ability effectively profitably commercialize imbruvica ibrutinib anticipated benefits abbvie 's merger pharmacyclics depend abbvie 's ability effectively profitably commercialize imbruvica including abbvie 's ability create meet continued market demand achieve market acceptance generate product sales ensure active pharmaceutical ingredient imbruvica finished product manufactured sufficient quantities compliance requirements fda similar foreign regulatory agencies acceptable quality pricing meet commercial demand ensure entire supply chain efficiently consistently delivers imbruvica abbvie 's customers commercialization imbruvica may successful due among things unexpected challenges competitors new safety issues concerns reported may impact narrow approved indications relative price imbruvica compared alternative treatment options changes label imbruvica restrict marketing commercialization imbruvica unsuccessful abbvie 's ability generate revenue product sales realize anticipated benefits merger adversely affected abbvie may acquire businesses license rights technologies products form alliances dispose assets could cause incur significant expenses could negatively affect profitability abbvie may pursue acquisitions technology licensing arrangements strategic alliances dispose assets part business strategy abbvie may complete transactions timely manner costeffective basis may realize expected benefits abbvie successful making acquisition products technologies acquired may successful may require significantly greater resources investments originally anticipated abbvie may able integrate acquisitions successfully existing business could incur assume significant debt unknown contingent liabilities abbvie could also experience negative effects reported results operations acquisition dispositionrelated charges amortization expenses related intangibles charges impairment long term assets effects could cause deterioration abbvie 's credit rating result increased borrowing costs interest expense additionally changes abbvie 's structure operations revenues costs efficiency resulting major transactions acquisitions divestitures mergers alliances restructurings strategic initiatives may result greater expected costs may take longer expected complete encounter difficulties including need regulatory approval appropriate abbvie dependent wholesale distributors distribution products united states accordingly results operations could adversely affected encounter financial difficulties three wholesale distributorsamerisourcebergen corporation cardinal health inc mckesson corporationaccounted substantially abbvie 's net revenues united states one significant wholesale distributors encounters financial difficulties distributor may decrease amount business abbvie abbvie may unable collect amounts distributor owes timely basis could negatively impact abbvie 's business results operations abbvie debt obligations could adversely affect business ability meet obligations amount debt abbvie incurred intends incur could important consequences abbvie investors consequences include among things requiring portion abbvie 's cash flow operations make interest payments debt reducing cash flow available fund capital expenditures corporate purposes grow abbvie 's business extent abbvie incurs additional indebtedness risks could increase addition abbvie 's cash flow operations may sufficient repay outstanding debt becomes due abbvie may able borrow money sell assets otherwise raise funds acceptable terms refinance debt abbvie may need additional financing future meet capital needs make opportunistic acquisitions financing may available favorable terms abbvie may need seek additional financing general corporate purposes example may need increase investment research development activities need funds make acquisitions abbvie may unable obtain desired additional financing terms favorable abbvie loses investment grade credit rating adequate funds available acceptable terms abbvie may unable fund expansion successfully develop enhance products respond competitive pressures could negatively affect abbvie 's business abbvie raises additional funds issuing debt entering credit facilities may subject limitations operations due restrictive covenants failure comply covenants could adversely affect abbvie 's business abbvie depends information technology failure systems could adversely affect abbvie 's business abbvie relies sophisticated information technology systems operate business systems potentially vulnerable malicious intrusion random attack loss data privacy breakdown although abbvie invested protection data information technology also monitors systems ongoing basis assurance efforts prevent breakdowns breaches abbvie 's information technology systems could adversely affect abbvie 's business factors material adverse effect abbvie 's profitability financial condition many factors affect abbvie 's results operations cash flows financial condition including changes interpretations laws regulations including changes accounting standards taxation requirements product marketing application standards environmental laws differences fair value measurement assets liabilities actual value particularly pension post employment benefits stockbased compensation intangibles goodwill contingent liabilities litigation absence recorded amount amount recorded minimum compared actual amount changes rate inflation including cost raw materials commodities supplies interest rates market value abbvie 's equity investments performance investments held employee benefit trusts changes creditworthiness counterparties transact business provide services abbvie employee benefit trusts changes ability third parties provide information technology accounting human resources payroll outsourced services abbvie meet contractual obligations abbvie changes business economic political conditions including war political instability terrorist attacks threat future terrorist activity related military action natural disasters cost availability insurance due foregoing events labor disputes strikes slowdowns forms labor union activity pressure thirdparty interest groups risks related abbvie 's common stock abbvie guarantee timing amount payment dividends common stock although abbvie expects pay regular cash dividends timing declaration amount payment future dividends stockholders fall within discretion abbvie 's board directors board 's decisions regarding payment dividends depend many factors abbvie 's financial condition earnings capital requirements debt service obligations industry practice legal requirements regulatory constraints factors board deems relevant information see item market registrant 's common equity related stockholder matters issuer purchases equity securities abbvie 's ability pay dividends depend ongoing ability generate cash operations access capital markets abbvie guarantee continue pay dividend future abbvie stockholder 's percentage ownership abbvie may diluted future future stockholder 's percentage ownership abbvie may diluted equity issuances capital market transactions equity awards abbvie granting abbvie 's directors officers employees acquisitions purposes abbvie 's employees options purchase shares common stock result conversion abbott stock options whole part abbvie stock options abbvie anticipates compensation committee grant additional stock options stockbased awards employees awards dilutive effect abbvie 's earnings per share could adversely affect market price abbvie 's common stock time time abbvie issue additional options stockbased awards employees abbvie 's employee benefits plans addition abbvie 's amended restated certificate incorporation authorizes abbvie issue without approval abbvie 's stockholders one classes series preferred stock designation powers preferences relative participating optional special rights including preferences abbvie 's common stock respecting dividends distributions abbvie 's board directors generally may determine terms one classes series preferred stock could dilute voting power reduce value abbvie 's common stock example abbvie could grant holders preferred stock right elect number abbvie 's directors events happening specified events right veto specified transactions similarly repurchase redemption rights liquidation preferences abbvie could assign holders preferred stock could affect residual value common stock certain provisions abbvie 's amended restated certificate incorporation amended restated bylaws delaware law may prevent delay acquisition abbvie could decrease trading price abbvie 's common stock abbvie 's amended restated certificate incorporation amended restated bylaws contain delaware law contains provisions intended deter coercive takeover practices inadequate takeover bids making practices bids unacceptably expensive bidder encourage prospective acquirors negotiate abbvie 's board directors rather attempt hostile takeover provisions include among others inability abbvie 's stockholders call special meeting division abbvie 's board directors three classes directors class serving staggered threeyear term provision stockholders may remove directors cause ability abbvie 's directors stockholders fill vacancies abbvie 's board directors requirement affirmative vote stockholders holding least percent abbvie 's voting stock required amend certain provisions abbvie 's amended restated certificate incorporation abbvie 's amended restated bylaws relating number term election abbvie 's directors filling board vacancies calling special meetings stockholders director officer indemnification provisions addition section delaware general corporation law provides subject limited exceptions persons acquire affiliated person acquires percent outstanding voting stock delaware corporation shall engage business combination corporation including merger consolidation acquisitions additional shares threeyear period following date person affiliates becomes holder percent corporation 's outstanding voting stock abbvie believes provisions protect stockholders coercive otherwise unfair takeover tactics requiring potential acquirors negotiate abbvie 's board directors providing abbvie 's board directors time assess acquisition proposal provisions intended make company immune takeovers however provisions apply even offer may considered beneficial stockholders could delay prevent acquisition abbvie 's board directors determines best interests abbvie abbvie 's stockholders provisions may also prevent discourage attempts remove replace incumbent directors cautionary statement regarding forwardlooking statements annual report contains certain forward looking statements regarding business strategies market potential future financial performance matters words believe expect anticipate project similar expressions among others generally identify forward looking statements speak date statements made matters discussed forward looking statements subject risks uncertainties factors could cause actual results differ materially projected anticipated implied forward looking statements particular information included item business item risk factors item management 's discussion analysis financial condition results operations contain forward looking statements forward looking statement expectation belief future results events expressed expectation belief based current plans expectations abbvie management expressed good faith believed reasonable basis assurance expectation belief result achieved accomplished factors could cause actual results events differ materially anticipated include matters described item risk factors item management 's discussion analysis financial condition results operations abbvie undertake obligation update forwardlooking statements included annual report reflect events circumstances date hereof unless abbvie required applicable securities law item b unresolved staff comments none item properties abbvie 's corporate offices located north waukegan road north chicago illinois abbvie 's principal manufacturing plants following locations united states outside united states abbott park illinois campoverde di aprilia italy barceloneta puerto rico cork ireland jayuya puerto rico ludwigshafen germany north chicago illinois sligo ireland worcester massachusetts leased property addition abbvie manufacturing facilities united states worldwide abbvie believes facilities suitable provide adequate production capacity united states including puerto rico abbvie one distribution center abbvie also four research development facilities united states located abbott park illinois north chicago illinois redwood city california worcester massachusetts outside united states abbvie 's principal research development facilities located ludwigshafen germany except noted principal plants united states listed owned abbvie subsidiaries abbvie remaining manufacturing plants facilities owned leased abbvie subsidiaries abbvie item legal proceedings information pertaining legal proceedings provided note entitled legal proceedings contingencies notes consolidated financial statements included item financial statements supplementary data incorporated reference herein item mine safety disclosures applicable executive officers registrant following table lists abbvie 's executive officers first appointed abbvie corporate officer december except otherwise indicated name age position richard gonzalez chairman board chief executive officer carlos alban executive vice president commercial operations william j chase executive vice president chief financial officer henry gosebruch executive vice president chief strategy officer laura j schumacher executive vice president external affairs general counsel corporate secretary michael e severino md executive vice president research development chief scientific officer timothy j richmond senior vice president human resources azita salekigerhardt phd senior vice president operations thomas hurwich vice president controller first appointed corporate officer december first appointed corporate officer june mr gonzalez abbvie 's chairman board chief executive officer served abbott 's executive vice president pharmaceutical products group responsible abbott 's worldwide pharmaceutical business including commercial operations research development manufacturing also served president abbott ventures inc abbott 's medical technology investment arm mr gonzalez joined abbott held various management positions briefly retiring including abbott 's president chief operating officer president chief operating officer abbott 's medical products group senior vice president president abbott 's former hospital products division hospira inc vice president president abbott 's health systems division divisional vice president general manager abbott 's diagnostics operations united states canada mr alban abbvie 's executive vice president commercial operations served abbott 's senior vice president proprietary pharmaceutical products global commercial operations senior vice president international pharmaceuticals vice president western europe canada vice president european operations mr alban joined abbott mr chase abbvie 's executive vice president chief financial officer served abbott 's vice president licensing acquisitions vice president treasurer divisional vice president controller abbott international mr chase joined abbott mr gosebruch abbvie 's executive vice president chief strategy officer worked years mergers acquisitions group jp morgan securities llc serving managing director since cohead north america mr gosebruch joined abbvie ms schumacher abbvie 's executive vice president external affairs general counsel corporate secretary responsible abbvie 's externallyfacing functions health economics outcomes research government affairs corporate responsibility brand communications also leads legal functions biotherapeutics strategy prior abbvie 's separation abbott ms schumacher served executive vice president general counsel corporate secretary senior vice president corporate secretary general counsel abbott abbvie ms schumacher also led licensing acquisition ventures early stage collaborations abbott ms schumacher also responsible office ethics compliance ms schumacher joined abbott serves board general dynamics corporation dr severino abbvie 's executive vice president research development chief scientific officer dr severino served amgen inc senior vice president global development corporate chief medical officer vice president global development vice president therapeutic area head general medicine inflammation global clinical development joined abbvie mr richmond abbvie 's senior vice president human resources served abbott 's divisional vice president compensation benefits group vice president talent rewards divisional vice president talent acquisition mr richmond joined abbott dr salekigerhardt abbvie 's senior vice president operations served abbott 's vice president pharmaceuticals manufacturing supply divisional vice president quality assurance global pharmaceutical operations dr saleki gerhardt joined abbott mr hurwich abbvie 's vice president controller served abbott 's vice president internal audit divisional vice president controller abbott diagnostics division mr hurwich joined abbott executive officers abbvie elected annually board directors officers elected board appointed chairman board officers either elected first meeting board directors held annual stockholder meeting appointed chairman board board meeting officer holds office successor duly elected appointed qualified officer 's death resignation removal family relationships executive officers listed part ii item market registrant 's common equity related stockholder matters issuer purchases equity securities principal market principal market abbvie 's common stock new york stock exchange nyse abbvie 's common stock also listed chicago stock exchange traded various regional electronic exchanges outside united states abbvie 's common stock listed nyse euronext paris six swiss exchange market price per share high low high low first quarter second quarter third quarter fourth quarter stockholders stockholders record abbvie common stock january dividends four quarterly dividends paid common stock first quarter cash dividend per share payable february second third fourth quarter dividends per share payable may august november respectively first quarter cash dividend per share payable february second third fourth quarter dividends per share payable may august november respectively october abbvie 's board directors declared increase quarterly cash dividend per share per share payable february stockholders record january timing declaration amount payment dividends abbvie future within discretion board directors depend upon many factors including abbvie 's financial condition earnings capital requirements operating subsidiaries covenants associated certain abbvie 's debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors moreover abbvie determines pay dividend future assurance continue pay dividends amount dividends performance graph following graph compares cumulative total returns abbvie sp index nyse arca pharmaceuticals index graph covers period january first day abbvie 's common stock began regularway trading nyse december graph assumes invested abbvie common stock index january also assumes reinvestment dividends stock price performance following graph necessarily indicative future stock price performance comparison cumulative total return performance graph furnished shall deemed filed sec subject section securities exchange act shall deemed incorporated reference filings securities act amended issuer purchases equity securities c total number maximum number shares b units approximate dollar average purchased value total price part shares units number paid publicly may shares per announced yet purchased units share plans period purchased unit programs plans programs october october november november december december total addition abbvie shares repurchased open market publicly announced program shares include following shares deemed surrendered abbvie pay exercise price connection exercise employee stock options october november december ii shares purchased open market benefit participants abbvie employee stock purchase plan october november december shares include shares surrendered abbvie satisfy minimum tax withholding obligations connection vesting restricted stock restricted stock units october abbvie announced board directors authorized purchase billion common stock purchases abbvie shares program may made time time management 's discretion program time limit discontinued time item selected financial data following table sets forth abbvie 's selected financial information derived audited consolidated financial statements years ended december ii audited combined financial statements years ended december historical financial statements periods prior january prepared standalone basis derived abbott 's consolidated financial statements accounting records former researchbased pharmaceutical business abbott part abbvie periods presented accordingly abbvie 's financial statements periods prior january presented combined basis reflect abbvie 's financial position results operations cash flows business operated part abbott prior separation conformity generally accepted accounting principles gaap united states selected financial information read conjunction financial statements accompanying notes included item financial statements supplementary data item management 's discussion analysis financial condition results operations years ended december millions except per share data statement earnings data net revenues net earningsab basic earnings per shareab diluted earnings per shareab cash dividends declared per share c na na weightedaverage basic shares outstandingd weightedaverage diluted shares outstandingd balance sheet data total assetse longterm debt lease obligationsef nanot applicable abbvie 's historical financial statements periods prior january reflected allocation expenses related certain abbott corporate functions including senior management legal human resources finance information technology quality assurance expenses allocated abbvie based direct usage benefit identifiable remainder allocated pro rata basis revenues headcount square footage number transactions measures abbvie considers expense allocation methodology results reasonable however allocations may indicative actual expenses would incurred abbvie operated independent standalone publiclytraded company periods presented accordingly historical financial information presented periods prior january may indicative results operations financial position would achieved abbvie independent standalone publiclytraded company periods shown abbvie 's performance periods subsequent december b results included higher expenses associated operating independent standalone publicly traded company historically derived financial statements periods prior january increases include impact interest expense debt issued november higher tax rate incremental costs operating independent company refer management 's discussion analysis financial condition results operations results operations discussion items affected comparability financial results c abbvie declared regular quarterly cash dividends aggregating per share common stock addition cash dividend per share common stock declared preseparation earnings january recorded reduction additional paidin capital january abbott distributed million shares abbvie common stock shareholders abbott common stock periods prior separation weightedaverage basic diluted shares outstanding based number shares abbvie common stock outstanding distribution date refer note audited consolidated financial statements included item financial statements supplementary data information regarding calculation basic diluted earnings per common share e may abbvie acquired pharmacyclics inc approximately billion including cash consideration billion equity consideration approximately million shares abbvie common stock valued billion connection acquisition abbvie issued billion aggregate principal amount unsecured senior notes approximately billion used finance acquisition pharmacyclics inc approximately billion used finance accelerated share repurchase agreement refer notes audited consolidated financial statements included item financial statements supplementary data information regarding acquisition pharmacyclics inc senior notes accelerated share repurchase program respectively f also includes current portion longterm debt lease obligations item management 's discussion analysis financial condition results operations following discussion analysis financial condition abbvie inc abbvie company december results operations three years period ended december commentary read conjunction consolidated financial statements accompanying notes appearing item financial statements supplementary data executive overview company overview abbvie global researchbased biopharmaceutical company formed following separation abbott laboratories abbott abbvie 's mission use expertise dedicated people unique approach innovation develop market advanced therapies address world 's complex serious diseases abbvie 's products focused treating conditions chronic autoimmune diseases rheumatology gastroenterology dermatology oncology including blood cancers virology including hepatitis c hcv human immunodeficiency virus hiv neurological disorders parkinson 's disease metabolic diseases including thyroid disease complications associated cystic fibrosis well serious health conditions abbvie also pipeline promising new medicines across important medical specialties immunology virologyliver disease oncology neurology cystic fibrosis women 's health abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly pharmacies patients outside united states sales made either directly customers distributors depending market served certain products comarketed co promoted companies abbvie approximately employees abbvie operates one business segmentpharmaceutical products may abbvie completed acquisition pharmacyclics inc pharmacyclics biopharmaceutical company develops commercializes novel therapies people impacted cancer flagship asset imbruvica ibrutinib novel orally active selective covalent inhibitor bruton 's tyrosine kinase btk part worldwide collaboration license agreement janssen biotech inc one janssen pharmaceutical companies johnson johnson janssen imbruvica approved use united states canada european union eu well countries worldwide united states abbvie comarkets imbruvica four indications approved us food drug administration fda prior acquisition date treatment patients mantle cell lymphoma mcl received least one prior therapy ii treatment patients chronic lymphocytic leukemia cll received least one prior therapy iii treatment cll patients deletion short arm chromosome del p cll iv treatment patients waldenstrom 's macroglobulinemia eu janssen markets imbruvica date acquisition imbruvica indicated eu treatment adult patients relapsed refractory mcl adult patients cll received least one prior therapy firstline presence p deletion tp mutation patients unsuitable chemoimmunotherapy acquisition accelerate abbvie 's clinical commercial presence oncology strengthen pipeline establish leadership position hematological oncology acquisition also accelerate abbvie 's revenue earnings growth diversify revenue base abbvie expects acquisition accretive earnings beginning refer note entitled licensing acquisitions arrangements notes condensed consolidated financial statements included part ii item financial statements supplementary data information regarding acquisition pharmacyclics financial results abbvie 's strategy focused delivering strong financial results advancing investing pipeline returning value shareholders ensuring strong sustainable growth business long term abbvie 's worldwide net revenues grew percent billion driven primarily continued strength humira united states internationally global launch abbvie 's interferonfree hcv treatment revenue growth key products including creon duodopa postacquisition revenues related imbruvica increases partially offset decline net revenues androgel principally due continued market declines entry generic competition androgel formulation well continued decline company 's lipid franchise unfavorable impact foreign exchange company 's financial performance included delivering fully diluted earnings per share including aftertax costs totaling million incurred connection acquisition integration pharmacyclics million aftertax charge purchase rare pediatric disease priority review voucher prv united therapeutics corporation million aftertax charge result entering exclusive worldwide license agreement cn diagnostics cn aftertax foreign exchange losses million result liquidation remaining foreign currency positions related terminated proposed combination shire plc shire aftertax charges million increase company 's litigation reserves million aftertax charge due achievement development milestone global collaboration infinity pharmaceuticals inc infinity refer note information regarding items abbvie 's financial performance also reflected improvement gross margin percent net revenues primarily due favorable product mix across product portfolio operating efficiencies impact foreign exchange rates financial results also reflected continued funding support abbvie 's emerging midand latestage pipeline assets continued investment abbvie 's growth brands global launch abbvie 's interferonfree hcv treatment viekira pak company generated cash flows operations billion cash flows enabled company pay cash dividends shareholders billion repurchase approximately million shares billion open market excluding shares repurchased accelerated repurchase agreement continue enhance pipeline licensing collaboration activities including million payment calico life sciences llc calico result satisfaction certain conditions research development rd collaboration calico charge acquired inprocess research development iprd recorded addition abbvie issued billion aggregate principal amount senior notes proceeds used finance acquisition pharmacyclics billion accelerated share repurchase agreement asr pursuant abbvie paid billion aggregate million shares abbvie 's common stock october abbvie 's board directors declared quarterly cash dividend per share common stock payable february reflects increase approximately percent previous quarterly rate per share common stock strategic objectives abbvie 's mission innovationdriven patientfocused specialty biopharmaceutical company capable achieving toptier financial performance outstanding execution consistent stream innovative new medicines abbvie intends continue advance mission number ways including growing revenues continued strong performance existing portfolio onmarket products including flagship brands humira imbruvica viekira pak well growth pipeline products ii expanding gross operating margins iii continued investment pipeline support opportunities immunology oncology virology well continued investment key onmarket products iv augmentation pipeline concerted focus strategic licensing acquisition partnering activity focus identifying compelling programs fit abbvie 's strategic criteria v returning cash shareholders via dividends share repurchases addition abbvie anticipates several regulatory submissions key data readouts key clinical trials abbvie expects achieve revenue growth objectives follows humira sales growth driving biologic penetration across disease categories increasing market leadership strong commercial execution expansion new indications hidradenitis suppurativa regulatory approval united states eu achieved uveitis regulatory submissions united states eu review approval expected imbruvica revenue growth driven increasing market share within four currently approved indications well indication expansion imbruvica firstline therapy cll currently priority review fda revenues also benefit full year imbruvica revenue viekira pak revenue growth driven continued uptake across geographies including japan second largest hcv market globally well indication expansion oncedaily fixeddosed formulation viekira pak treat genotype gt hcv currently review favorable impact pipeline products approved currently regulatory review approval expected including venetoclax empliciti elotuzumab zinbryta daclizumab pipeline products described greater detail section labeled research development included part item abbvie remains committed driving continued expansion gross operating margins expects achieve objective productivity initiatives supply chain ongoing efficiency programs optimize manufacturing commercial infrastructure administrative costs general corporate expenses continued leverage revenue growth abbvie also remains committed returning cash shareholders via dividends share repurchases research development research innovation cornerstones abbvie 's business global biopharmaceutical company abbvie 's longterm success depends great extent ability continue discover develop innovative pharmaceutical products acquire collaborate compounds currently development biotechnology pharmaceutical companies abbvie 's pipeline currently includes compounds indications clinical development individually collaboration license agreements focused important medical specialties immunology oncology virologyliver disease neurology along targeted investments renal disease cystic fibrosis women 's health programs mid latestage development following sections summarize transitions significant programs phase development phase development well developments significant phase registration programs abbvie expects multiple phase programs transition phase programs significant clinical programs approved submitted abbvie submitted review received approval following significant latestage development programs immunology fda granted humira orphan drug designation treatment moderatetosevere hidradenitis suppurativa hs painful chronic inflammatory skin disease abbvie 's supplemental biological license application bla united states marketing authorization eu approved fda european medicines agency ema respectively approval indication represents thirteenth indication humira major geographies around world april abbvie announced european commission ec granted marketing authorization humira treatment severe chronic plaque psoriasis children adolescence four years age inadequate response inappropriate candidates topical therapy phototherapies ec decision humira approved use indication member states eu abbvie submitted regulatory applications united states eu use humira treatment uveitis abbvie expects receive regulatory approval oncology july abbvie announced ec granted marketing authorization imbruvica first treatment option specifically approved treatment adult patients waldenstrom 's macroglobulinemia rare slow growing blood cancer pharmacyclics received fda approval imbruvica patients waldenstrom 's macroglobulinemia january ec approval triggered million milestone payment janssen september abbvie announced submitted supplemental new drug application snda fda imbruvica treatmentnave cll patients snda based results phase resonate study evaluated efficacy safety imbruvica versus traditional chemotherapy chlorambucil treatmentnave cll patients aged years older application received priority review november abbvie submitted snda fda labeling considerations based safety efficacy results phase helios trial investigating use imbruvica bendamustine rituximab versus placebo plus bendamustine rituximab patients relapsedrefractory cll small lymphocytic lymphoma february fda granted imbruvica orphan drug designation treatment patients extranodal marginal zone lymphoma abbvie submitted regulatory applications united states eu venetoclax abt inhibitor bcell lymphoma bcl protein developed collaboration genentech roche holding ag priority review status granted fda validation provided ema submissions venetoclax also phase development patients relapsedrefractory cll addition venetoclax granted three breakthrough therapy designations fda treatment cll previously treated relapsedrefractory patients p deletion mutation ii combination rituximab treatment patients relapsedrefractory cll including patients chromosome p deletion iii combination hypomethylating agents treatment patients untreated treatmentnave acute myeloid leukemia ineligible receive standard induction therapy highdose chemotherapy registration submissions submitted fda ec empliciti elotuzumab signaling lymphocyte activation molecule slamdirected immunostimulatory antibody developed partnership bristolmyers squibb bms firstline relapsedrefractory multiple myeloma mm subsequently ema validated review marketing authorization application empliciti elotuzumab treatment mm combination therapy adult patients received one prior therapies application granted accelerated assessment ema 's committee medicinal products human use chmp addition fda approved empliciti elotuzumab treatment mm combination therapy patients received one three prior therapies first fda approval immunestimulatory antibody mm indication empliciti marketed bms virologyliver disease january abbvie announced ec granted marketing authorizations alloral shortcourse interferonfree treatment viekirax ombitasvirparitaprevirritonavir tablets exviera dasabuvir tablets treatment approved without ribavirin rbv patients gt chronic hcv infection including compensated liver cirrhosis hiv coinfection patients opioid substitution therapy liver transplant recipients additionally viekiraxexviera approved use rbv genotype gt chronic hcv patients abbvie 's regulatory application japan company 's alloral rbv interferonfree week two directacting antiviral treatment ombitasvirparitaprevirritonavir obvptvr dosed daily approved september treatment patients gt chronic hcv infection july fda approved abbvie 's regulatory application technivie obvptvr tablets combination rbv treatment adults gt chronic hcv infection cirrhosis technivie first alloral interferonfree directacting antiviral treatment approved united states adult patients gt chronic hcv infection abbvie submitted regulatory application united states oncedaily fixeddosed formulation viekira pak treat gt hcv proposed dosing fixeddose formulation three oral tablets taken daily meal without rbv abbvie anticipates regulatory action new formulation fda accepted abbvie 's snda granted priority review viekira pak without rbv patients genotype b gtb chronic hcv infection compensated cirrhosis childpugh neurology january abbvie announced fda approved duopa carbidopa levodopa enteral suspension treatment motor fluctuations people advanced parkinson 's disease duopa administered using small portable infusion pump delivers carbidopa levodopa directly small intestine continuous hours via procedurallyplaced tube product sold name duodopa outside united states abbvie collaborating biogen develop zinbryta daclizumab anticd monoclonal antibody treatment relapsingremitting form multiple sclerosis ms february registration submission zinbryta made united states followed eu submission march march abbvie biogen announced ema validated companies ' marketing authorization application zinbryta treatment relapsing forms ms eu validation confirms submission complete signifies initiation review process chmp april abbvie biogen announced fda accepted review registration submission united states significant developments transitions significant programs phase phase development well significant developments included following immunology january abbvie announced commencement phase clinical trial program study use abbvie 's oncedaily formulation abt internally developed investigational selective janus kinase jak inhibitor treatment rheumatoid arthritis phase trial abt treatment crohn 's disease also ongoing abbvie received decision ec regarding compliance pediatric investigation plan humira ensures necessary data obtained studies children result positive decision company seeking extension eu member state supplementary protection certificate held approved extend humira composition matter patent eu six months april october oncology july abbvie initiated phase study use veliparib abt parpinhibitor treatment ovarian cancer combination chemotherapy veliparib also phase development various forms breast lung cancer abbvie recently initiated first phase clinical trial imbruvica solid tumors trial evaluate safety efficacy imbruvica combination gemcitabine nabpaclitaxel firstline treatment patients metastatic pancreatic adenocarcinoma virologyliver disease october consultation fda product inserts united states viekira pak technivie updated recommended childpugh b patients contraindication patients childpugh b cirrhosis patients classified childpugh c remained contraindicated since approval january abbvie initiated phase clinical trial program evaluating safety efficacy nextgeneration alloral daily pangenotypic rbvfree investigational hcv regimen includes abt nsa protease inhibitor abt nsa inhibitor abbvie developing novel oral gonadotropinreleasing hormone gnrh antagonist elagolix collaboration neurocrine biosciences neurocrine treatment endometriosisrelated pain uterine fibroids january abbvie announced initiation first two planned phase studies evaluating safety efficacy elagolix treatment patients uterine fibroids abbvie make milestone payment million neurocrine upon enrollment first patient elagolix latestage development endometriosis abbvie entered collaboration galapagos nv galapagos develop filgotinib oral jak inhibitor following thorough review available data abbvie announced exercise right inlicense filgotinib galapagos pursuant terms global collaboration agreement galapagos rights filgotinib reverted solely galapagos abbvie also augmented pipeline strategic licensing partnering activities including inlicensing antitau antibody abbv e treatment alzheimer 's disease neurological disorders cn privately held protein diagnostic therapeutic discovery company refer note notes consolidated financial statements included item financial statements supplementary data information regarding license agreement cn results operations net revenues comparisons presented constant currency rates reflect comparative local currency net revenues prior year 's foreign exchange rates measure provides information change net revenues assuming foreign currency exchange rates changed prior current period abbvie believes nongaap measure change net revenues constant currency rates used conjunction gaap measure change net revenues actual currency rates may provide complete understanding company 's operations facilitate analysis company 's results operations particularly evaluating performance one period another percent change actual constant currency currency rates rates years ended millions united states international net revenues following table details abbvie 's worldwide net revenues percent change actual constant currency currency rates rates years ended december millions humira united states international total imbruvica united states na na na na collaboration revenues na na na na total na na na na viekira united states nm nm international na na na na total nm nm creon united states synagis international lupron united states international total synthroid united states kaletra united states international total androgel united states sevoflurane united states international total duodopa united states nm na nm na international total dyslipidemia products united states total net revenues nmnot meaningful nanot applicable following discussion analysis abbvie 's net revenues product presented constant currency basis global humira sales increased percent primarily result market growth across therapeutic categories geographies higher market share approval new indications favorable pricing certain geographies united states humira revenues increased percent percent driven prescription volume favorable pricing market growth across indications internationally humira revenues increased percent percent driven primarily growth across indications certain geographies abbvie continues pursue several new indications help differentiate humira competing products add sustainability future growth humira net revenues imbruvica represent product revenues united states well collaboration revenues related abbvie 's percent share imbruvica profit outside united states following completion acquisition pharmacyclics may abbvie expects imbruvica significant contributor revenue growth abbvie launched hcv regimen viekira pak united states following fda approval middecember launched viekiraxexviera eu january addition growth approved markets international revenues continued increase product approved additional geographies net revenues viekira pak reflect shipment launch quantities market support full commercial launch net revenues creon increased percent percent driven primarily continued market growth higher market share creon maintains market leadership pancreatic enzyme market synagis seasonal product majority sales occurring first fourth quarters net revenues increased percent percent revenues reflected changes demand certain markets well unfavorable comparison driven less severe respiratory syncytial virus season global lupron net revenues increased percent primarily due increased demand favorable pricing united states lupron continues hold leadership position maintains significant share market global kaletra net revenues declined percent percent primarily due lower market share resulting impact increasing competition hiv marketplace androgel net revenues declined percent percent primarily due continued decline overall us testosterone replacement market entry generic competition androgel formulation january company expects us testosterone replacement market continue decline net revenues duodopa abbvie 's therapy advanced parkinson 's disease approved europe international markets grew percent abbvie 's regulatory submission duopa united states approved fda january abbvie expects net revenues duopa united states continue gradually increase product gains acceptance marketplace net revenues abbvie 's consolidated lipid franchise included tricor trilipix niaspan simcor advicor declined percent percent due introduction generic versions products us market generic competition began november tricor july trilipix september niaspan abbvie voluntarily withdrawn simcor advicor market discontinued distribution december net revenues declined percent primarily due reduced demand driven market share declines reduction price several abbvie 's mature onmarket products gross margin percent change years ended december millions gross margin percent net revenues gross margin reflected favorable impact product mix across product portfolio including humira operational efficiencies price increases partially offset effect unfavorable foreign exchange rates loss exclusivity lipid franchise gross margin also includes milestone revenue million collaboration partner related company 's oncology program gross margin also includes royalty income million relating prior periods result settlement licensing arrangement lower amortization expense intangible assets partially offset million impairment charge intangible asset selling general administrative percent change years ended december millions selling general administrative percent net revenues selling general administrative sga expenses declined compared principally due absence transactionrelated costs totaling billion incurred connection termination proposed combination shire discussed note notes consolidated financial statements sga expenses also included million charge related branded prescription drug fee due issuance final rules resulted additional year expense refer note information excluding items sga expenses increased reflecting increased selling marketing support new products including global launch viekira well spending relating new indications geographic expansion humira growth brands sga expenses also included pharmacyclics acquisition integration costs million charges aggregating million increase company 's litigation reserves restructuring charges million increased costs partially offset impact favorable foreign exchange rates research development acquired inprocess research development percent change years ended december millions research development percent net revenues acquired inprocess research development rd expenses included pharmacyclics acquisition integration costs million million charge related purchase priority review voucher third party million charge recorded due achievement development milestone collaboration infinity postacquisition rd expenses pharmacyclics restructuring charges million rd expenses included regulatory milestone payments million made collaboration partner regulatory milestones related company 's hcv program restructuring charges million respectively rd expenses otherwise reflected added funding support company 's emerging mid latestage pipeline assets continued pursuit additional humira indications increases partially offset impact favorable foreign exchange rates iprd expenses included charge million result entering exclusive worldwide license agreement cn develop commercialize antitau antibodies treatment alzheimer 's disease neurological disorders iprd expenses included charge million result entering global collaboration infinity develop commercialize duvelisib treatment patients cancer iprd expense included charge million result entering global license agreement ablynx nv develop commercialize alx charge million result entering global collaboration alvine pharmaceuticals inc develop alv charge million result entering global collaboration galapagos cystic fibrosis therapies charges totaling million result entering several arrangements refer note notes consolidated financial statements additional information related company 's collaborations arrangements operating expenses operating expenses included million charge related rd collaboration agreement entered september calico discover develop commercialize new therapies patients agerelated diseases nonoperating expenses interest expense net million million million comprised primarily interest expense outstanding debt interest expense net increased due may issuance billion aggregate principal amount senior notes issued primarily finance acquisition pharmacyclics accelerated share repurchase program interest expense net also included million bridge financing related fees incurred connection acquisition pharmacyclics interest expense net included million financing related fees incurred connection terminated proposed combination shire abbvie entered certain undesignated forward contracts hedge anticipated foreign currency cash outflows associated proposed combination shire net foreign exchange loss included losses million associated shirerelated forward contracts net foreign exchange loss included losses totaling million reflect completed liquidation company 's remaining foreign currency positions related terminated proposed combination shire nonoperating expense net included impairment charges totaling million related certain company 's equity investment securities nonoperating income net primarily consisted income million resolution contractual agreement income tax expense effective income tax rate percent percent percent effective tax rate fluctuates year year due allocation company 's taxable earnings among jurisdictions well certain discrete factors events year including acquisitions collaborations effective income tax rate included tax benefit million reduction state valuation allowances effective income tax rate included state valuation allowances million additional expenses million related branded prescription drug fee nondeductible financial position liquidity capital resources years ended december millions cash flows provided byused operating activities investing activities financing activities cash flows provided operations billion compared billion increase primarily due improved results operations due revenue growth improvement operating margin well absence aftertax transaction financingrelated costs billion incurred connection termination proposed combination shire including net foreign exchange losses related settlement undesignated forward contracts used hedge anticipated foreign currency cash flows exit certain foreign currency positions cash provided operating activities also reflected abbvie 's voluntary contributions main domestic defined benefit plan million million respectively abbvie also made voluntary contribution million plan subsequent december abbvie also paid million purchase priority review voucher united therapeutics corporation realized excess tax benefits associated stockbased compensation totaled million million million respectively presented consolidated statements cash flows outflow within operating section inflow within financing section investing activities primarily included billion cash consideration paid acquire pharmacyclics may net cash acquired million investing activities also included cash outflows related acquisitions investments million including million payment calico accrued due satisfaction certain conditions rd collaboration million related exclusive worldwide license agreement cn develop commercialize antitau antibodies treatment alzheimer 's disease neurological disorders million paid infinity due achievement development milestone collaboration agreement cash outflows related acquisitions investments totaled million including million paid infinity related global collaboration develop duvelisib ipi million fund novel rd collaboration calico cash flows investing activities also reflected capital expenditures net sales purchases shortterm investments capital expenditures included purchase small molecule active pharmaceutical ingredient manufacturing facility singapore abbvie incurred additional expenditures build new biologics facility site produce bulk drug substance humira well support abbvie 's biologic pipeline company issued redeemed commercial paper balance commercial paper outstanding million million december respectively abbvie may issue additional commercial paper retire commercial paper meet liquidity requirements needed may company issued billion aggregate principal amount senior notes various maturities approximately billion net proceeds used finance acquisition pharmacyclics billion net proceeds used finance accelerated share repurchase program described september abbvie entered threeyear billion term loan credit facility day billion term loan credit facility november abbvie drew term facilities used proceeds refinance billion senior notes matured connection acquisition pharmacyclics company paid million costs relating billion day bridge term loan credit agreement well million costs relating issuance senior notes cash dividend payments totaled billion billion october abbvie announced board directors declared increase company 's quarterly cash dividend per share per share beginning dividend payable february stockholders record january timing declaration amount payment dividends within discretion board directors depend upon many factors including abbvie 's financial condition earnings capital requirements operating subsidiaries covenants associated certain abbvie 's debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors october abbvie 's board directors authorized billion stock repurchase program march board directors authorized billion increase existing stock repurchase program anticipation executing accelerated share repurchase agreement financial institution connection acquisition pharmacyclics may abbvie entered executed billion asr morgan stanley co llc morgan stanley pursuant terms asr morgan stanley made initial delivery approximately million shares abbvie 's common stock may represented approximately percent total shares expected delivered asr subsequently morgan stanley delivered additional million shares abbvie 's common stock abbvie final settlement asr abbvie recorded aggregate billion purchase price reduction stockholders ' equity addition asr company repurchased approximately million shares billion open market approximately million shares million open market abbvie settled million open market purchases purchases abbvie shares program may made time time management 's discretion program time limit discontinued time abbvie 's remaining stock repurchase authorization billion december refer note additional information related asr cash equivalents also negatively impacted net unfavorable exchange rate changes totaling million million respectively principally due weakening euro foreign currencies translation company 's euro denominated assets cash denominated foreign currencies abbvie increased concentration cash denominated foreign currencies accumulated anticipation terminated proposed combination shire significant portion cash equivalents december considered reinvested indefinitely foreign subsidiaries abbvie expect reinvestment affect liquidity capital resources funds needed operations united states abbvie would required accrue pay us income taxes repatriate funds abbvie believes sufficient sources liquidity support assumption disclosed amount undistributed earnings december reinvested indefinitely credit risk abbvie monitors economic conditions creditworthiness customers government regulations funding domestically abroad abbvie regularly communicates customers regarding status receivable balances including payment plans obtains positive confirmation validity receivables abbvie establishes allowance accounts receivable probable collected abbvie also monitors potential periodically utilized factoring arrangements mitigate credit risk although receivables included arrangements historically material amount total outstanding receivables abbvie continues business foreign governments certain countries including greece portugal italy spain experienced deterioration credit economic conditions substantially abbvie 's trade receivables greece portugal italy spain governmental health systems abbvie continues monitor economic health economy southern europe heightened economic concerns still exist outstanding net governmental receivables countries december follows net receivables one year net receivables past due millions greece portugal italy spain total company also continues business foreign governments certain oilexporting countries experienced deterioration economic conditions including venezuela saudi arabia outstanding net governmental receivables related saudi arabia million december refer item quantitative qualitative disclosures market riskforeign currency risk additional disclosures related venezuela due decline price oil liquidity issues certain countries may result delays collection receivables global economic conditions customerspecific factors may require company reevaluate collectability receivables company could potentially incur credit losses currently abbvie believe economic conditions southern europe oilexporting countries material impact company 's liquidity cash flow financial flexibility however government funding become unavailable countries significant adverse changes reimbursement practices occur abbvie may able collect entire balance outstanding december credit facility access capital credit ratings credit facility abbvie currently billion fiveyear revolving credit facility matures october revolving credit facility enables company borrow funds unsecured basis variable interest rates contains various covenants december company compliance credit facility covenants commitment fees credit facility material amounts outstanding credit facility december access capital company intends fund shortterm longterm financial obligations mature cash hand future cash flows operations issuing additional debt company 's ability generate cash flows operations issue debt enter financing arrangements acceptable terms could adversely affected material decline demand company 's products solvency customers suppliers deterioration company 's key financial ratios credit ratings material unfavorable changes business conditions current time company believes sufficient financial flexibility issue debt enter financing arrangements attract longterm capital acceptable terms support company 's growth objectives credit ratings april following announcement proposed combination pharmacyclics moody 's investor service confirmed baa senior unsecured longterm rating prime shortterm rating revised ratings outlook negative stable march standard poor 's rating services sp affirmed abbvie 's corporate credit rating senior unsecured debt rating commercial paper rating revised ratings outlook negative stable additional changes company 's credit ratings unfavorable changes ratings may adverse impact future financing arrangements however would affect company 's ability draw credit facility would result acceleration scheduled maturities company 's outstanding debt contractual obligations following table summarizes abbvie 's estimated contractual obligations december less one three three five millions total one year years years five years shortterm borrowings longterm debt capital lease obligations including current portion interest longterm debta future minimum noncancelable operating lease commitments purchase obligations otherb longterm liabilitiesc total includes estimated future interest payments longterm debt securities capital lease obligations interest payments debt calculated future periods using interest rates effect end projected interest payments include related effects interest rate swap agreements certain projected interest payments may differ future based changes floating interest rates factors events projected interest payments pertain obligations agreements outstanding december refer notes discussion regarding company 's debt instruments related interest rate agreements outstanding december annual interest capital lease obligations material b includes company 's significant unconditional purchase obligations commitments exceed company 's projected requirements made normal course business c amounts less one year includes voluntary contribution million abbvie made main domestic defined benefit plan subsequent december amounts otherwise exclude pension postemployment benefits related deferred compensation cash outflows timing funding uncertain dependent future movements interest rates investment returns changes laws regulations variables also included amount components longterm liabilities including restructuring refer notes information abbvie enters rd collaboration arrangements third parties may require future milestone payments third parties contingent upon achievement certain development regulatory commercial milestones individually arrangements material one annual reporting period however milestones multiple products covered arrangements would happen reached reporting period aggregate charge expense could material results operations period business perspective payments viewed positive signify product successfully moving development generating likely generate cash flows product sales possible predict reasonable certainty whether milestones achieved timing achievement result potential payments included table contractual obligations refer note consolidated financial statements discussion collaboration arrangements critical accounting policies estimates preparation financial statements accordance generally accepted accounting principles united states requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses summary company 's significant accounting policies included note consolidated financial statements certain policies considered critical significantly impact company 's financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain actual results may vary estimates revenue recognition abbvie recognizes revenue persuasive evidence arrangement exists delivery occurred sales price fixed determinable collectability sales price reasonably assured revenue product sales recognized title risk loss passed customer rebates abbvie provides rebates pharmacy benefit managers state government medicaid programs insurance companies administer medicare drug plans wholesalers group purchasing organizations government agencies private entities rebate chargeback accruals recorded reduction revenue period related product sold rebates chargebacks totaled billion billion billion respectively rebate amounts typically based upon volume purchases using contractual statutory prices may vary product payer type rebate factors used calculations accrual rebate include identification products subject rebate applicable price terms estimated lag time sale payment rebate significant order establish rebate chargeback accruals company uses internal external data estimate level inventory distribution channel rebate claims processing lag time type rebate estimate rebate percentage net price company tracks sales product customer payer company evaluates inventory data reported wholesalers available prescription volume information product pricing historical experience factors order determine adequacy reserves abbvie regularly monitors reserves records adjustments rebate trends rebate programs contract terms legislative changes significant events indicate change reserve appropriate historically adjustments rebate accruals material net earnings following table analysis three largest rebate accruals chargeback allowances comprise approximately percent total consolidated rebate chargebacks charged revenues remaining rebate provisions charged gross revenues significant determination operating earnings medicaid managed medicare care wholesaler millions rebates rebates chargebacks balance december provisions payments balance december provisions payments balance december provisions payments balance december cash discounts product returns allowances cash discounts product returns totaled million million million respectively recorded reduction revenue period related product sold reserve cash discounts readily determinable company 's experience payment history fairly consistent product returns reliably estimated based company 's historical return experience pension postemployment benefits abbvie engages outside actuaries assist determination obligations costs plans direct obligations abbvie valuation funded status net periodic benefit cost plans calculated using actuarial assumptions significant assumptions reviewed annually include discount rate expected longterm rate return plan assets health care cost trend rates significant assumptions used determining calculations disclosed note consolidated financial statements discount rate selected based current market rates highquality fixedincome investments december year abbvie employs yieldcurve approach countries robust bond market exists yield curve developed using highquality bonds yield curve approach reflects plans ' specific cash flows ie duration calculating benefit obligations applying specific spot rates along yield curve beginning abbvie also reflect plans ' specific cash flows apply specific spot rates along yield curve calculating service cost interest cost portions expense countries abbvie reviews various indices corporate bond government bond benchmarks estimate discount rate abbvie 's assumed discount rate significant effect amounts reported defined benefit pension postemployment plans december used calculation net periodic benefit cost basis point change assumed discount rate would following effects abbvie 's calculation net periodic benefit costs projected benefit obligations december basis point millions brackets denote reduction increase decrease defined benefit plans service cost interest cost projected benefit obligation postemployment plans service cost interest cost projected benefit obligation effective december abbvie elected change method uses estimate service interest cost components net periodic benefit costs abbvie pension plan primary postemployment benefit plan united states well certain international defined benefit plans postemployment benefit plans based current economic conditions change expected reduce abbvie 's net periodic benefit cost approximately million result change refer note information regarding change expected longterm rate return based asset allocation historical performance current view expected future returns abbvie considers inputs longterm focus avoid shortterm market influences current longterm rate return plan assets supported historical performance trust 's actual target asset allocation abbvie 's assumed expected longterm rate return significant effect amounts reported defined benefit pension plans december used calculation net periodic benefit cost percentage point change assumed expected longterm rate return plan assets would increased decreased net period benefit cost plans million health care cost trend rate selected reviewing historical trends current views projected future health care cost increases current health care cost trend rate supported historical trend experience plan assumed health care cost trend rates significant effect amounts reported health care plans december used calculation net periodic benefit cost percentage point change assumed health care cost trend rates would following effects abbvie 's calculation net periodic benefit costs projected benefit obligation december one percentage point millions brackets denote reduction increase decrease service cost interest cost projected benefit obligation income taxes abbvie accounts income taxes asset liability method provisions federal state foreign income taxes calculated reported pretax earnings based current tax laws deferred taxes provided using enacted tax rates future tax consequences temporary differences differences financial statement carrying amount assets liabilities respective tax bases tax benefits carryforwards valuation allowance established maintained based currently available information likely portion deferred tax asset realized litigation company subject contingencies various claims legal proceedings investigations regarding product liability intellectual property commercial securities matters arise normal course business refer note information loss contingency provisions recorded probable losses management 's best estimate loss best estimate made minimum loss contingency amount within probable range recorded accordingly abbvie often initially unable develop best estimate loss therefore minimum amount could zero recorded information becomes known either minimum loss amount increased resulting additional loss provisions best estimate made also resulting additional loss provisions occasionally best estimate amount changed lower amount events result expectation favorable outcome previously expected valuation goodwill intangible assets abbvie acquired may continue acquire significant intangible assets connection business combinations abbvie records fair value transactions involving purchase sale intangible assets occur frequency companies pharmaceuticals industry valuations usually based discounted cash flow analysis incorporating stage completion discounted cash flow model requires assumptions timing amount future net cash flows risk cost capital terminal values market participants factors significantly affect value intangible asset iprd acquired business combination capitalized indefinitelived intangible asset regulatory approval obtained time accounted definitelived asset amortized estimated useful life iprd acquired transactions business combinations expensed immediately unless deemed alternative future use payments made third parties subsequent regulatory approval capitalized amortized remaining useful life abbvie reviews recoverability definitelived intangible assets whenever events changes circumstances indicate carrying value asset may recoverable goodwill indefinitelived intangible assets relate iprd reviewed impairment annually event occurs could result impairment refer note consolidated financial statements information annually company tests goodwill impairment first assessing qualitative factors determine whether likely fair value less carrying amount factors considered assessment include general macroeconomic conditions conditions specific industry market cost factors could significant effect earnings cash flows overall financial performance whether sustained declines company 's share price company concludes likely fair value reporting unit less carrying amount quantitative impairment test performed abbvie tests indefinitelived intangible assets using quantitative impairment test quantitative impairment tests company uses estimated future cash flow approach requires significant judgment respect future volume revenue expense growth rates changes working capital use foreign currency exchange rates selection appropriate discount rate asset groupings assumptions estimates estimates assumptions used consistent company 's business plans market participant 's views company similar companies use alternative estimates assumptions could increase decrease estimated fair value assets potentially result different impacts company 's results operations actual results may differ company 's estimates recent accounting pronouncements may financial accounting standards board fasb issued accounting standards update asu summary amendments create revenue contracts customers topic assets deferred costscontracts customers subtopic amendments asu supersede current revenue recognition requirements core principal new guidance entity recognize revenue depict transfer promised goods services customers amount reflects consideration entity expects entitled exchange goods services abbvie apply amendments using one following two methods retrospectively prior reporting period presented ii modified retrospectively cumulative effect initially applying amendments recognized date initial application july fasb issued asu revenue contracts customers topic deferral effective date deferred effective date asu one year entities accordingly asu effective annual reporting periods beginning december including interim periods within reporting period early application permitted annual reporting periods beginning december including interim periods within reporting period abbvie currently assessing timing adoption impact adopting guidance consolidated financial statements implementation approach used april fasb issued asu interestimputation interest subtopic simplifying presentation debt issuance costs amendments asu require debt issuance costs related recognized debt liability presented balance sheet direct deduction carrying amount debt liability consistent debt discounts standard effective annual interim periods beginning december early adoption permitted retrospective basis abbvie elected early adopt new standard effective three months ended june result abbvie reclassified approximately million million net deferred financing costs december previously classified prepaid expenses current assets longterm assets respectively longterm debt lease obligations current noncurrent total debt issuance costs classified reduction longterm debt lease obligations current noncurrent million december september fasb issued asu business combinations topic simplifying accounting measurementperiod adjustments standard requires acquirer recognize adjustments provisional amounts identified measurement period reporting period adjustment amounts determined entities currently required retrospectively apply adjustments made provisional amounts recognized business combination standard effective fiscal years beginning december including interim periods within fiscal years guidance applied prospectively measurement period adjustments occur effective date guidance earlier application permitted financial statements issued abbvie elected early adopt standard effective year ended december impact adoption material november fasb issued asu income taxes topic balance sheet classification deferred taxes standard requires deferred tax liabilities assets classified noncurrent classified statement financial position entities currently required separate deferred income tax liabilities assets current noncurrent amounts classified statement financial position amendments require noncurrent presentation jurisdiction effective financial statements issued annual periods beginning december earlier application permitted beginning interim annual reporting period guidance applied either prospectively deferred tax liabilities assets retrospectively periods presented abbvie elected early adopt standard prospective basis effective december order simplify presentation deferred tax assets liabilities prior periods retrospectively adjusted january fasb issued asu financial instrumentsoverall subtopic recognition measurement financial assets financial liabilities standard requires several targeted changes including equity investments except accounted equity method accounting result consolidation investee measured fair value changes fair value recognized net income new guidance also changes certain disclosure requirements aspects current us gaap amendments applied cumulativeeffect adjustment balance sheet beginning fiscal year adoption standard effective fiscal years starting december including interim periods within fiscal years standard permit early adoption exception certain targeted provisions abbvie currently assessing impact timing adopting guidance consolidated financial statements item quantitative qualitative disclosures market risk company exposed risk earnings cash flows equity could adversely impacted changes foreign exchange rates interest rates certain derivative instruments used available costeffective basis hedge company 's underlying economic exposures refer note entitled financial instruments fair value measures notes consolidated financial statements included item financial statements supplementary data information regarding company 's financial instruments hedging strategies foreign currency risk abbvie 's primary net foreign currency exposures euro japanese yen british pound various abbvie foreign subsidiaries enter foreign currency forward exchange contracts manage exposures changes foreign exchange rates anticipated transactions denominated currency functional currency local entity contracts designated cash flow hedges variability cash flows due changes foreign currency exchange rates markedtomarket resulting gains losses reflected accumulated comprehensive income loss abbvie 's consolidated balance sheets deferred gains losses contracts included cost products sold time products sold third party generally exceeding twelve months december abbvie held billion billion respectively notional amounts contracts abbvie enters foreign currency forward exchange contracts manage exposure foreign currency denominated trade payables receivables intercompany loans contracts designated hedges markedtomarket resulting gains losses reflected net foreign exchange abbvie 's consolidated statements earnings generally offset losses gains foreign currency exposure managed december abbvie held notional amounts billion billion respectively foreign currency forward exchange contracts following table reflects total foreign currency forward contracts outstanding december fair fair weighted carrying weighted carrying average value average value contract exchange receivable contract exchange receivable millions amount rate payable amount rate payable receive primarily us dollars exchange following currencies euro japanese yen british pound currencies na na total company estimates percent appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts million december realized appreciation would negatively affect earnings remaining life contracts would offset gains underlying hedged items percent appreciation believed reasonably possible nearterm change foreign currencies gains losses hedging instruments offset losses gains hedged transactions reduce earnings stockholders ' equity volatility relating foreign exchange functional currency company 's venezuela operations us dollar due hyperinflationary status venezuelan economy currency restrictions enacted venezuela require approval venezuelan government exchange venezuelan bolivars vef us dollars require exchange made official exchange rate established government first quarter venezuelan government expanded number exchange mechanisms three rates exchange december official rate supplementary system administration foreign currency sicad rate approximately foreign exchange marginal system simadi rate approximately consolidated financial statements year ended december company used official rate vef per us dollar reported million net monetary assets million net revenues denominated venezuelan bolivar february venezuelan government announced plans devalue official rate vef us dollars eliminate sicad rate vef us dollars devaluation venezuelan bolivar result charge abbvie 's results operations first quarter abbvie 's net monetary assets denominated venezuelan bolivar converted rate vef us dollars december company would reported devaluation loss million abbvie 's net monetary assets denominated venezuelan bolivar converted simadi rate december company would reported devaluation loss million company predict whether devaluations venezuelan currency whether use official rate continue supported evolving facts circumstances could result significant charge abbvie 's results operations time interest rate risk interest rate swaps used manage company 's exposure changes interest rates fair value fixedrate debt effect hedges change fixed interest rate variable rate december abbvie interest rate hedge contracts totaling billion billion respectively company estimates increase interest rates basis points would decrease fair value interest rate swap contracts approximately million december realized fair value reduction would affect earnings remaining life contracts company estimates increase basis points longterm interest rates would decrease fair value longterm debt billion december basis point change believed reasonably possible nearterm change interest rates market price sensitive investments abbvie holds equity securities pharmaceutical biotechnology companies traded public stock exchanges fair value investments approximately million million december respectively abbvie monitors investments temporary declines market value charges impairment losses net earnings temporary decline value occurs hypothetical percent decrease share prices investments would decrease fair value investments million december percent decrease believed reasonably possible nearterm change share prices nonpublicly traded equity securities abbvie holds equity securities pharmaceutical biotechnology companies traded public stock exchanges carrying value investments approximately million million december respectively abbvie monitors investments temporary declines market value charges impairment losses net earnings temporary decline estimated value occurs abbvie recorded impairment charges totaling million related certain company 's investments nonpublicly traded equity securities item financial statements supplementary data consolidated financial statements consolidated statements earnings consolidated statements comprehensive income consolidated balance sheets consolidated statements equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm abbvie inc subsidiaries consolidated statements earnings years ended december millions except per share data net revenues cost products sold selling general administrative research development acquired inprocess research development expense total operating costs expenses operating earnings interest expense net net foreign exchange loss expense income net earnings income tax expense income tax expense net earnings per share data basic earnings per share diluted earnings per share cash dividends declared per common share weightedaverage basic shares outstanding weightedaverage diluted shares outstanding january cash dividend per share common stock declared preseparation earnings recorded reduction additional paidin capital accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated statements comprehensive income years ended december millions net earnings foreign currency translation adjustments net tax benefit expense pension postemployment benefits net tax expense benefit unrealized gains marketable equity securities net tax expense hedging activities net tax benefit expense comprehensive loss income comprehensive income accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated balance sheets december millions except share data assets current assets cash equivalents shortterm investments accounts receivables net inventories net deferred income taxes prepaid expenses total current assets investments property equipment net intangible assets net accumulated amortization goodwill assets total assets liabilities equity current liabilities shortterm borrowings current portion longterm debt lease obligations accounts payable accrued liabilities total current liabilities longterm debt lease obligations deferred income taxes longterm liabilities commitments contingencies stockholders ' equity common stock par value authorized shares issued shares december respectively common stock held treasury cost shares december respectively additional paidincapital retained earnings accumulated comprehensive loss total stockholders ' equity total liabilities equity accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated statements equity accumulated common additional net parent years ended shares common treasury paidin retained comprehensive company december millions outstanding stock stock capital earnings loss investment total balance december separationrelated adjustments reclassification parent company net investment connection separation issuance common shares separation net earnings comprehensive income net tax dividends declared share repurchases stockbased compensation plans balance december net earnings comprehensive loss net tax dividends declared share repurchases stockbased compensation plans balance december net earnings comprehensive loss net tax dividends declared common shares issued pharrmacyclics inc stockholders share repurchases stockbased compensation plans balance december accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated statements cash flows years ended december millions brackets denote cash outflows cash flows operating activities net earnings adjustments reconcile net earnings net cash operating activities depreciation amortization intangible assets stockbased compensation upfront costs milestones related collaborations net changes operating assets liabilities net acquisitions accounts receivables inventories prepaid expenses assets accounts payable liabilities cash flows operating activities cash flows investing activities acquisition pharmacyclics inc net cash acquired acquisitions investments acquisitions property equipment purchases investment securities sales maturities investment securities cash flows investing activities cash flows financing activities net change shortterm borrowings proceeds issuance longterm debt repayments longterm debt capital leases debt issuance cost dividends paid purchases treasury stock proceeds exercise stock options net transactions abbott laboratories excluding noncash items net cash flows financing activities effect exchange rate changes cash equivalents net increase decrease cash equivalents cash equivalents beginning year cash equivalents end year supplemental information interest paid net portion capitalized income taxes paid supplemental schedule noncash investing financing activities issuance common shares associated acquisition pharmacyclics inc cash flows operating activities included impact transaction financingrelated costs incurred connection terminated proposed combination shire plc refer note additional information accompanying notes integral part consolidated financial statements abbvie inc subsidiaries notes consolidated financial statements note background basis presentation background principal business abbvie inc abbvie company discovery development manufacture sale broad line pharmaceutical products abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses substantially abbvie 's net revenues united states three wholesalers outside united states products sold primarily customers distributors depending market served abbvie incorporated delaware april january abbvie became independent publiclytraded company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott 's shareholders abbvie 's common stock began trading regularway ticker symbol abbv new york stock exchange january separationrelated adjustments totaling billion recorded stockholders ' equity separationrelated adjustments additional paidin capital principally reflected dividends abbvie shareholders declared preseparation earnings first quarter transfer certain pension plan liabilities assets abbott abbvie upon legal split plans addition abbvie 's historical financial statements prior january derived abbott 's records separationrelated adjustments also included adjustment accumulated comprehensive loss reflect appropriate opening balances associated currency translation adjustments related abbvie 's legal entities separation date refer note information regarding separation pension plans connection separation abbvie abbott entered transition services agreements covering certain corporate support back office services abbvie historically received abbott services included information technology accounts payable payroll receivables collection treasury financial functions well order entry warehousing engineering support quality assurance support administrative services agreements facilitated separation allowing abbvie operate independently prior establishing standalone back office functions across organization transition services agreements original terms months option oneyear extension majority transaction service agreements expired without extension december certain limited exceptions remaining transition services agreements terminated prior december years ended december abbvie incurred million million million respectively separationrelated expenses principally classified selling general administrative expenses sga consolidated statements earnings charges principally related information technology legal regulatory fees basis historical presentation certain portion abbvie 's operations legal transfer abbvie 's assets net liabilities occur separation abbvie january due time required transfer marketing authorizations satisfy regulatory requirements certain countries terms separation agreement abbott abbvie responsible business activities conducted abbott behalf subject risks entitled benefits generated operations assets result related assets liabilities results operations reported abbvie 's consolidated financial statements years ended december net revenues related operations totaled approximately million million million respectively exception venezuela operations transferred abbvie december note summary significant accounting policies use estimates financial statements prepared accordance us gaap necessarily include amounts based estimates assumptions management actual results could differ amounts significant estimates include amounts rebates pension post employment benefits income taxes litigation valuation intangible assets goodwill financial instruments inventory accounts receivable exposures basis consolidation consolidated financial statements years ended december include accounts abbvie subsidiaries controlling interest maintained controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities abbvie determined primary beneficiary investments companies abbvie significant influence controlling interest accounted using equity method abbvie 's share earnings losses reported expense income net consolidated statements earnings investments generally accounted using cost method intercompany balances transactions eliminated certain reclassifications made conform prior period consolidated financial statements current period presentation revenue recognition abbvie recognizes revenue persuasive evidence arrangement exists delivery occurred sales price fixed determinable collectability sales price reasonably assured revenue product sales recognized title risk loss passed customer provisions discounts rebates sales incentives customers returns adjustments provided period related revenues recorded rebate amounts typically based upon volume purchases using contractual statutory prices may vary product payer type rebate factors used calculations accrual rebate include identification products subject rebate applicable price terms estimated lag time sale payment rebate significant sales incentives customers material historical data readily available reliable used estimating amount reduction gross revenues revenue launch new product improved version existing product shipments excess customer 's normal requirements recorded conditions noted met situations management records returns reserve revenue necessary sales product rights marketable products recorded revenue upon disposition rights research development expenses internal research development rd expenses expensed incurred clinical trial costs incurred third parties expensed contracted work performed contingent milestone payments due third parties research development collaborations pre commercialization milestones milestone payment obligations expensed milestone results achieved payments made third parties subsequent regulatory approval capitalized intangible assets amortized cost products sold remaining useful life related product collaborations arrangements company enters collaborative agreements third parties develop commercialize drug candidates collaborative activities may include joint research development commercialization new products abbvie generally receives certain licensing rights arrangements collaborations often require upfront payments may include additional milestone research development cost sharing royalty profit share payments contingent upon occurrence certain future events linked success asset development commercialization upfront payments associated collaborative arrangements development stage expensed acquired inprocess research development iprd expenses consolidated statements earnings subsequent payments made partner achievement milestones development stage expensed rd expenses consolidated statements earnings milestone achieved milestone payments made partner subsequent regulatory approval capitalized intangible assets amortized cost products sold estimated useful life related asset royalties expensed cost products sold consolidated statements earnings incurred advertising costs associated advertising expensed incurred included sga expenses consolidated statements earnings advertising expenses million million million respectively pension postemployment benefits abbvie records annual expenses relating defined benefit pension postemployment plans based calculations include various actuarial assumptions including discount rates assumed asset rates return compensation increases turnover rates health care cost trend rates abbvie reviews actuarial assumptions annual basis makes modifications assumptions based current rates trends actuarial losses gains amortized remaining service attribution periods employees corridor method accordance rules accounting postemployment benefits differences expected longterm return plan assets actual annual return amortized net periodic benefit cost fiveyear period income taxes income taxes accounted asset liability method provisions federal state foreign income taxes calculated reported pretax earnings based current tax laws deferred taxes provided using enacted tax rates future tax consequences temporary differences differences financial statement carrying amount assets liabilities respective tax bases tax benefits carryforwards valuation allowance established maintained based currently available information likely portion deferred tax asset realized cash equivalents cash equivalents include time deposits money market funds original maturities time purchase three months less investments shortterm investments consist primarily time deposits heldtomaturity debt securities investments marketable equity securities classified availableforsale recorded fair value unrealized holding gains losses net tax included accumulated comprehensive loss aoci abbvie 's consolidated balance sheets investments equity securities traded public stock exchanges heldtomaturity debt securities recorded cost abbvie reviews carrying value investments quarter determine whether temporary decline fair value exists abbvie considers factors affecting investee factors affecting industry investee operates general equity market trends company considers length time investment 's fair value cost nearterm prospects recovery abbvie determines temporary decline occurred cost basis investment written charge expense income net consolidated statements earnings availableforsale investment 's unrealized loss reclassified aoci expense income net consolidated statements earnings accounts receivable accounts receivable stated net realizable value allowance gross accounts receivable reflects best estimate probable losses inherent receivables portfolio determined basis historical experience specific allowances known troubled accounts currently available information accounts receivable written reasonable means collect full amount including litigation appropriate exhausted allowance million million december respectively inventories inventories valued lower cost firstin firstout basis market cost includes material conversion costs inventories net consist following december millions finished goods workinprocess raw materials inventories net inventories net december included million acquired acquisition pharmacyclics inc pharmacyclics may refer note additional information property equipment december millions land buildings equipment construction progress property equipment gross less accumulated depreciation property equipment net depreciation property equipment recorded straightline basis estimated useful lives assets estimated useful life buildings ranges years five years equipment leasehold improvements amortized life related facility lease including renewal periods appropriate asset whichever shorter depreciation expense million million million respectively equipment includes certain computer software software development costs incurred connection developing obtaining software internal use amortized three years assets capital leases included property equipment consolidated balance sheets material litigation contingencies loss contingency provisions recorded probable liability incurred amount liability reasonably estimated based existing information best estimate made minimum loss contingency amount probable range recorded legal fees expensed incurred abbvie accrues product liability claims undiscounted basis probable liability incurred amount liability reasonably estimated based existing information liabilities evaluated quarterly adjusted necessary additional information becomes available receivables insurance recoveries product liability claims recorded assets undiscounted basis probable recovery realized business combinations results operations acquired companies included abbvie 's results operations beginning respective acquisition dates assets acquired liabilities assumed recognized date acquisition respective fair values excess fair value consideration transferred estimated fair values net assets acquired recognized goodwill contingent consideration recognized estimated fair value acquisition date determined utilizing probability weighted discounted cash flow model subsequent changes fair value contingent payments recognized expense income net consolidated statements earnings fair value assets acquired liabilities assumed certain cases may subject revision based final determination fair value legal costs due diligence costs business valuation costs business acquisition costs expensed incurred goodwill intangible assets intangible assets acquired business combination recorded fair value using discounted cash flow model discounted cash flow model requires assumptions timing amount future net cash flows risk cost capital terminal values market participants definitelived intangibles amortized estimated useful lives abbvie reviews recoverability definitelived intangible assets whenever events changes circumstances indicate carrying value asset may recoverable abbvie first compares projected undiscounted cash flows generated asset carrying value undiscounted cash flows intangible asset less carrying value intangible asset intangible asset written fair value usually discounted cash flow amount loss recorded equal excess asset 's net carrying value fair value cash flows identified individual asset review applied lowest level cash flows largely independent cash flows assets liabilities goodwill indefinitelived assets amortized subject impairment review annually frequently indicators impairment exist impairment goodwill would occur carrying amount reporting unit exceeded fair value reporting unit indefinite lived intangible assets consist capitalized iprd would occur fair value iprd intangible asset less carrying amount company tests goodwill impairment first assessing qualitative factors determine whether likely fair value less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative impairment test performed abbvie tests indefinitelived intangible assets using quantitative impairment test quantitative impairment test company uses estimated future cash flow approach requires significant judgment respect future volume revenue expense growth rates changes working capital use foreign currency exchange rates selection appropriate discount rate asset groupings assumptions estimates estimates assumptions used consistent company 's business plans market participant 's views company similar companies use alternative estimates assumptions could increase decrease estimated fair value assets potentially result different impacts company 's results operations actual results may differ company 's estimates based upon company 's recent annual impairment test performed third quarter company concluded goodwill impaired intangible impairment charges recorded abbvie recorded impairment charge million related certain onmarket product rights japan due increased generic competition charge included cost products sold consolidated statements earnings acquired inprocess research development initial costs rights iprd projects acquired asset acquisition expensed iprd consolidated statements earnings unless project alternative future use costs include initial payments incurred prior regulatory approval connection research development collaboration agreements provide rights develop manufacture market andor sell pharmaceutical products fair value iprd projects acquired business combination capitalized accounted indefinitelived intangible assets underlying project receives regulatory approval point intangible asset accounted definitelived intangible asset discontinuation point intangible asset written development costs incurred acquisition expensed incurred indefinite definitelived assets subject impairment reviews discussed previously foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using period end exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized comprehensive loss income oci consolidated statements comprehensive income net assets subsidiaries highly inflationary economies remeasured functional currency reporting currency remeasurement recognized net foreign exchange loss consolidated statements earnings immaterial years presented derivatives derivative instruments recognized either assets liabilities fair value abbvie 's consolidated balance sheets classified current longterm based scheduled maturity instrument accounting changes fair value derivative instrument depends whether formally designated qualifies part hedging relationship applicable accounting standards type hedging relationship derivatives formally designated hedges company assesses inception quarterly thereafter whether hedging derivatives highly effective offsetting changes fair value cash flows hedged item changes fair value derivative designated fair value hedge hedged item attributable hedge risk recognized earnings immediately fair value hedges used hedge interest rate risk associated certain company 's fixedrate debt effective portions changes fair value derivative designated cash flow hedge reported aoci subsequently recognized earnings consistent underlying hedged item cash flow hedges used manage exposures changes foreign currency exchange rates derivatives designated qualify hedges adjusted fair value current earnings determined derivative longer highly effective hedge company discontinues hedge accounting prospectively gains losses immediately reclassified aoci earnings relating hedged forecasted transactions longer probable occurring gains losses relating terminations effective cash flow hedges forecasted transactions still probable occurring deferred recognized consistent income loss recognition underlying hedged items terminations fair value hedges result fair value adjustments hedged items date termination new bases accreted par value date maturity derivatives including designated hedge principally classified operating section consolidated statements cash flows consistent underlying hedged item recent accounting pronouncements may financial accounting standards board fasb issued accounting standards update asu summary amendments create revenue contracts customers topic assets deferred costscontracts customers subtopic amendments standard supersede current revenue recognition requirements core principal new guidance entity recognize revenue depict transfer promised goods services customers amount reflects consideration entity expects entitled exchange goods services abbvie apply amendments using one following two methods retrospectively prior reporting period presented ii modified retrospectively cumulative effect initially applying amendments recognized date initial application july fasb issued asu revenue contracts customers topic deferral effective date deferred effective date asu one year entities accordingly standard effective annual reporting periods beginning december including interim periods within reporting period early application permitted annual reporting periods beginning december including interim periods within reporting period abbvie currently assessing timing adoption impact adopting guidance consolidated financial statements implementation approach used april fasb issued asu interestimputation interest subtopic simplifying presentation debt issuance costs amendments asu require debt issuance costs related recognized debt liability presented balance sheet direct deduction carrying amount debt liability consistent debt discounts standard effective annual interim periods beginning december early adoption permitted retrospective basis abbvie elected early adopt new standard effective three months ended june result abbvie reclassified approximately million million net deferred financing costs december previously classified prepaid expenses current assets longterm assets respectively longterm debt lease obligations current noncurrent total debt issuance costs classified reduction longterm debt lease obligations current noncurrent million december september fasb issued asu business combinations topic simplifying accounting measurementperiod adjustments standard requires acquirer recognize adjustments provisional amounts identified measurement period reporting period adjustment amounts determined entities currently required retrospectively apply adjustments made provisional amounts recognized business combination standard effective fiscal years beginning december including interim periods within fiscal years guidance applied prospectively measurement period adjustments occur effective date guidance earlier application permitted financial statements issued abbvie elected early adopt standard effective year ended december impact adoption material november fasb issued asu income taxes topic balance sheet classification deferred taxes asu requires deferred tax liabilities assets classified noncurrent classified statement financial position entities currently required separate deferred income tax liabilities assets current noncurrent amounts classified statement financial position amendments require noncurrent presentation jurisdiction effective financial statements issued annual periods beginning december earlier application permitted beginning interim annual reporting period guidance applied either prospectively deferred tax liabilities assets retrospectively periods presented abbvie elected early adopt standard prospective basis effective december order simplify presentation deferred tax assets liabilities prior periods retrospectively adjusted january fasb issued asu financial instrumentsoverall subtopic recognition measurement financial assets financial liabilities standard requires several targeted changes including equity investments except accounted equity method accounting result consolidation investee measured fair value changes fair value recognized net income new guidance also changes certain disclosure requirements aspects current us gaap amendments applied cumulativeeffect adjustment balance sheet beginning fiscal year adoption standard effective fiscal years starting december including interim periods within fiscal years standard permit early adoption exception certain targeted provisions abbvie currently assessing impact timing adopting guidance consolidated financial statements note supplemental financial information interest expense net years ended december millions interest expense interest income interest expense net interest expense net included million bridge financingrelated costs incurred connection acquisition pharmacyclics refer note additional information interest expense net included million financing related fees incurred connection terminated proposed combination shire plc company incorporated jersey shire expense income net expense income net includes income expense resolution certain contractual agreements impairments equity securities gains losses sale equity securities expense net primarily consisted impairments certain equity securities income net primarily consisted income million resolution contractual agreement accounts payable accrued liabilities december millions sales rebates accounts payable dividends payable salaries wages commissions royalty license arrangements accounts payable accrued liabilities longterm liabilities december millions pension postemployment benefits liabilities unrecognized tax benefits longterm liabilities note earnings per share abbvie calculates earnings per share eps using dilutive treasury stock twoclass method twoclass method earnings allocation formula determines earnings per share common stock participating securities according dividends declared participation rights undistributed earnings method earnings distributed undistributed allocated common shares participating securities based respective rights receive dividends addition participating securities may include certain performancebased awards may otherwise excluded calculation eps treasurystock method abbvie 's forfeitable restricted stock units rsus restricted stock awards rsas including performancebased awards participate dividends basis common shares dividends nonforfeitable holder declared result forfeitable rsus rsas meet definition participating security periods presented twoclass method dilutive dilutive effect unvested rsus rsas approximately million million million shares respectively excluded denominator calculation diluted eps awards otherwise would included calculation eps treasury stock method additionally earnings distributed undistributed allocable participating securities including performancebased awards otherwise included calculation eps treasury stock method excluded numerator calculation basic diluted earnings per share twoclass method earnings allocable participating securities million million million respectively described note abbvie entered executed billion accelerated share repurchase agreement asr morgan stanley co llc morgan stanley may pursuant abbvie paid billion initial delivery million shares abbvie 's common stock initial delivery shares represented approximately percent total shares expected delivered asr morgan stanley subsequently delivered additional million shares abbvie 's common stock abbvie final settlement asr august purposes calculating eps abbvie reflected asr repurchase abbvie common stock number common shares issuable stockbased compensation plans excluded computation earnings per common share effect would antidilutive material periods presented note licensing acquisitions arrangements acquisition pharmacyclics may abbvie acquired pharmacyclics tender offer approximately billion including cash consideration billion equity consideration billion pharmacyclics biopharmaceutical company develops commercializes novel therapies people impacted cancer pharmacyclics markets imbruvica ibrutinib bruton 's tyrosine kinase btk inhibitor targeting bcell malignancies outstanding pharmacyclics share exchanged cash fair market value abbvie common stock ii cash iii fair market value abbvie common stock election holder subject election proration consideration percent cash percent abbvie common stock total consideration acquisition pharmacyclics approximately billion consisting cash approximately million shares abbvie common stock summarized follows millions fair value abbvie common stock issued pharmacyclics stockholders cash consideration paid pharmacyclics stockholders cash consideration paid pharmacyclics equity award holders total consideration acquisition pharmacyclics accounted business combination using acquisition method accounting method requires among things assets acquired liabilities assumed recognized fair value acquisition date valuation assets acquired liabilities assumed acquisition yet finalized december result abbvie recorded preliminary estimates fair value assets acquired liabilities assumed acquisition date completion valuation occur later one year acquisition date may result significant changes recognized assets liabilities following table summarizes preliminary fair values assets acquired liabilities assumed may acquisition date millions assets acquired liabilities assumed cash equivalents shortterm investments accounts receivables inventories assets intangible assets definitelived developed product rights definitelived license agreements indefinitelived research development accounts payable accrued liabilities deferred income taxes longterm liabilities total identifiable net assets goodwill total assets acquired liabilities assumed fair market value stepup adjustment inventories million amortized cost products sold inventory sold customers expected period approximately months acquisition date intangible assets relate imbruvica developed product rights iprd united states related additional indications imbruvica contractual rights imbruvica profits losses outside united states result collaboration agreement janssen biotech inc affiliates janssen one janssen pharmaceutical companies johnson johnson refer note additional information regarding collaboration janssen acquired definitelived intangible assets amortized weightedaverage estimated useful life years using estimated pattern economic benefit estimated fair value iprd identifiable intangible assets determined using income approach valuation technique provides estimate fair value asset based market participant expectations cash flows asset would generate remaining useful life significant assumptions inherent development asset valuations include estimated net cash flows year asset product including net revenues cost sales rd costs selling marketing costs working capitalcontributory asset charges appropriate discount rate select order measure risk inherent future cash flow stream assessment asset 's life cycle potential regulatory commercial success risks competitive trends impacting asset cash flow stream well factors goodwill calculated excess consideration transferred net assets recognized represents future economic benefits arising assets acquired could individually identified separately recognized specifically goodwill recognized acquisition pharmacyclics includes expected synergies including ability leverage respective strengths business expanding combined company 's product portfolio acceleration clinical commercial presence oncology establishment strong leadership position hematological oncology goodwill deductible tax purposes acquisition date december abbvie 's consolidated statement earnings included net revenues million pretax operating loss million associated acquisition operating loss included million acquisitionrelated compensation expense million inventory stepup intangible asset amortization million transaction integration costs costs million recorded within sga expenses million within rd expenses million within cost products sold consolidated statement earnings pro forma financial information following table presents unaudited pro forma combined results operations abbvie pharmacyclics acquisition pharmacyclics occurred january years ended december millions except per share data net revenues net earnings basic earnings per share diluted earnings per share unaudited pro forma financial information prepared using acquisition method accounting based historical financial information abbvie pharmacyclics order reflect occurrence acquisition january required unaudited pro forma financial information includes adjustments reflect incremental amortization expense incurred based current preliminary fair values identifiable intangible assets acquired incremental cost products sold related fair value adjustments associated acquisitiondate inventory additional interest expense associated issuance debt finance acquisition reclassification acquisition integration financingrelated costs incurred year ended december year ended december unaudited pro forma financial information necessarily indicative consolidated results operations would acquisition completed january addition unaudited pro forma financial information projection future results operations combined company reflect expected realization cost savings synergies associated acquisition licensing acquisitions activity excluding acquisition pharmacyclics cash outflows related acquisitions investments totaled million million million respectively abbvie recorded iprd charges million million million respectively abbvie also recorded operating expenses million related collaboration calico life sciences llc calico significant arrangements impacting require contingent milestone payments summarized addition significant arrangements described abbvie entered several arrangements resulting charges iprd million million million connection individually insignificant arrangements entered abbvie could make additional payments billion upon achievement certain development regulatory commercial milestones cn diagnostics march abbvie entered exclusive worldwide license agreement cn diagnostics cn develop commercialize antitau antibodies treatment alzheimer 's disease neurological disorders part agreement abbvie made initial upfront payment million expensed iprd upon achievement certain development regulatory commercial milestones abbvie could make additional payments million well royalties net sales calico life sciences llc september abbvie calico entered novel rd collaboration agreement discover develop commercialize new therapies patients agerelated diseases including neurodegeneration cancer abbvie recorded million operating expense consolidated statement earnings related commitments agreement million paid million paid early calico responsible research early development first five years continue advance collaboration projects phase ten year period abbvie option exclusively license collaboration compounds completion phase abbvie support calico early rd efforts upon option exercise would responsible latestage development commercial activities collaboration costs profits shared equally companies post option exercise infinity pharmaceuticals inc september abbvie entered global collaboration agreement infinity pharmaceuticals inc infinity develop commercialize duvelisib ipi treatment patients cancer part agreement abbvie made initial upfront payment million expensed iprd third quarter abbvie made additional payment million recorded rd expense consolidated statement earnings due achievement development milestone collaboration agreement upon achievement certain development regulatory commercial milestones abbvie could make additional payments million united states companies jointly commercialize duvelisib share equally potential profits outside united states abbvie responsible commercialization duvelisib infinity eligible receive tiered doubledigit royalties net product sales ablynx nv september abbvie entered global collaboration agreement ablynx nv develop commercialize antiilr nanobody alx treatment inflammatory diseases including rheumatoid arthritis systemic lupus erythematosus resulting charge iprd million upon achievement certain development regulatory commercial milestones abbvie could make additional payments million well royalties net sales galapagos nv september abbvie recorded charge iprd million result entering global collaboration galapagos nv galapagos discover develop commercialize cystic fibrosis therapies upon achievement certain development regulatory commercial milestones abbvie could make additional payments million well royalties net sales alvine pharmaceuticals inc may abbvie entered global collaboration alvine pharmaceuticals inc develop alv novel oral treatment patients celiac disease part agreement abbvie made initial upfront payment million expensed iprd second quarter december abbvie make additional payments pursuant arrangement activity united therapeutics corporation august abbvie entered agreement purchase rare pediatric disease priority review voucher prv united therapeutics corporation prv entitles abbvie receive fda priority review single new drug application biologics license application reduces target review time could lead expedited approval exchange prv abbvie made payment million recorded rd expenses consolidated statement earnings operating cash outflow consolidated statement cash flows abbvie intends use prv existing rd project termination proposed combination shire october abbvie 's board directors withdrew previous recommendation abbvie stockholders favor proposed combination shire recommended stockholders vote proposed combination october abbvie shire mutually agreed terminate proposed combination company incurred transaction financingrelated costs totaling billion billion recorded sga expenses million recorded interest expense net consolidated statement earnings included sga expenses break fee billion tax deductible paid abbvie shire october result termination proposed combination addition company recorded million net foreign exchange losses primarily due undesignated forward contracts entered hedge anticipated foreign currency cash outflows associated terminated proposed combination shire exit certain foreign currency positions forward contracts settled first quarter abbvie recorded additional foreign exchange losses million reflect completed liquidation remaining foreign currency positions refer note information regarding forward contracts entered anticipation proposed combination shire note collaboration janssen biotech inc december pharmacyclics entered worldwide collaboration license agreement janssen joint development commercialization imbruvica novel orally active selective covalent inhibitor btk certain compounds structurally related imbruvica oncology indications excluding immune inflammatory mediated diseases conditions psychiatric psychological diseases conditions united states outside united states collaboration provides janssen exclusive license commercialize imbruvica outside united states coexclusively abbvie united states parties responsible development manufacturing marketing products generated result collaboration collaboration set duration specific expiration date provides potential future development regulatory approval milestone payments million abbvie collaboration includes cost sharing arrangement associated collaboration activities except certain cases general janssen responsible approximately percent collaboration development costs abbvie responsible remaining percent collaboration development costs abbvie janssen share pretax profits losses equally commercialization products janssen responsible exclusive rights commercialize imbruvica outside united states parties coexclusive rights commercialize products united states abbvie principal end customer product sales operating expenses costs incurred collaboration reported respective expense line items net payments due reimbursements due janssen revenues profit share costs related sales imbruvica united states included net revenues cost products sold respectively amounts payable abbvie janssen imbruvica sales outside united states included net revenues janssen 's share pretax profits united states collaboration million recorded within cost products sold consolidated statement earnings abbvie 's share pretax profits outside united states cost sharing expenses collaboration million million respectively december abbvie 's receivable janssen million abbvie 's payable janssen million classified accounts receivables net accounts payable accrued liabilities respectively abbvie 's consolidated balance sheet note goodwill intangible assets goodwill following table summarizes changes carrying amount abbvie 's goodwill millions balance december additions foreign currency translation adjustments balance december additions foreign currency translation adjustments balance december goodwill additions related acquisition pharmacyclics refer note additional information regarding acquisition latest impairment assessment goodwill completed third quarter december accumulated goodwill impairment losses future impairment tests goodwill performed annually third quarter earlier indicators impairment exist intangible assets net following table summarizes abbvie 's intangible assets gross net gross net carrying accumulated carrying carrying accumulated carrying december millions amount amortization amount amount amortization amount definitelived intangible assets developed product rights license agreements total definitelived intangible assets indefinitelived research development total intangible assets net intangible assets finite useful lives amortized estimated useful lives range years average years years developed product rights license agreements respectively additions primarily due acquisition pharmacyclics amounts amortized using estimated pattern economic benefit refer note additional information regarding acquisition additions primarily related acquisition million amortizable intangible assets license agreements market product rights united states average amortization period years amortization expense million million million respectively included cost products sold consolidated statements earnings anticipated annual amortization expense definite lived intangible assets recorded december million million million billion billion third quarter impairment charge million recorded related certain onmarket product rights japan due increased generic competition charge based discounted cash flow analysis included cost products sold consolidated statement earnings indefinitelived intangible assets represent acquired iprd associated products yet received regulatory approval indefinitelived intangible assets december relate iprd acquired business combination increase primarily due acquisition pharmacyclics latest impairment assessment intangible assets subject amortization completed third quarter impairment charges recorded impairment charges recorded related indefinitelived intangible assets material future impairment tests indefinitelived intangible assets performed annually third quarter earlier indicators impairment exist note restructuring plans abbvie continuously evaluates operations identify opportunities optimize manufacturing rd operations commercial infrastructure administrative costs respond changes business environment example conjunction loss expected loss exclusivity certain products result abbvie management periodically approves individual restructuring plans achieve objectives plans individually material restructuring charges recorded million million million respectively primarily related employee severance contractual obligations charges recorded cost products sold rd expenses sga expenses consolidated statements earnings based classification affected employees operations following summarizes cash activity restructuring reserve millions accrued balance december restructuring charges payments adjustments accrued balance december restructuring charges payments adjustments accrued balance december restructuring charges payments adjustments accrued balance december payments adjustments included million reversal previously recorded restructuring reserve due company 's evaluation prior year decision exit manufacturing facility note debt credit facilities commitments contingencies following summary abbvie 's longterm debt effective effective interest interest rate rate december millions senior notes issued floating rate notes due notes due notes due notes due notes due notes due senior notes issued notes due notes due notes due notes due notes due notes due term loan facilities floating rate notes due floating rate notes due fair value hedges unamortized bond discounts unamortized deferred financing costs total longterm debt lease obligations current portion noncurrent portion excludes effect related interest rate swaps september abbvie entered billion threeyear term loan credit agreement billion day term loan credit agreement collectively term loan facilities november abbvie drew term loan facilities used proceeds refinance billion senior notes matured november borrowings term loan facilities bear interest variable rates adjust based abbvie 's public debt ratings term loan facilities may prepaid without penalty upon prior notice contain customary covenants company compliance december may company issued billion aggregate principal amount unsecured senior notes senior notes rank equally unsecured unsubordinated indebtedness company abbvie may redeem senior notes prior maturity redemption price equal principal amount senior notes redeemed plus makewhole premium except notes due abbvie may redeem senior notes par one six months prior maturity debt issuance costs incurred connection offering totaled million amortized respective terms senior notes interest expense net consolidated statements earnings senior notes contain customary covenants company compliance december approximately billion net proceeds issuance senior notes used finance acquisition pharmacyclics approximately billion net proceeds used finance asr morgan stanley refer notes additional information related acquisition pharmacyclics asr respectively march abbvie entered billion day bridge term loan credit agreement bridge loan support planned acquisition pharmacyclics amounts drawn bridge loan terminated result company 's may issuance senior notes interest expense net include million costs related bridge loan abbvie outstanding billion aggregate principal amount unsecured senior notes issued abbvie may redeem senior notes series time senior notes series time time redemption price equal principal amount senior notes redeemed plus makewhole premium december company compliance senior note covenants shortterm borrowings december shortterm borrowings included million million respectively commercial paper borrowings weightedaverage interest rate shortterm borrowings percent percent respectively october abbvie entered billion fiveyear revolving credit facility matures october replaced billion five year revolving credit facility revolving credit facility enables company borrow funds unsecured basis variable interest rates contains various covenants december company compliance credit facility covenants commitment fees abbvie 's revolving credit facilities material amounts outstanding credit facility december december maturities longterm debt capital lease obligations following table summarizes abbvie 's future minimum lease payments noncancelable operating leases debt maturities future minimum lease payments capital lease obligations december debt maturities operating capital years ended december millions leases leases thereafter total obligations commitments fair value hedges unamortized bond discounts deferred financing costs total debt lease obligations lease expense million million million abbvie 's operating leases generally include renewal options provide company pay taxes maintenance insurance operating costs leased property december annual future minimum lease payments capital lease obligations material debt maturities capital leases include billion floating rate notes due drawn day term loan credit agreement contingencies guarantees connection separation abbvie indemnified abbott liabilities resulting operation abbvie 's business income tax liabilities respect periods prior distribution date liabilities agreed abbvie abbott abbvie material exposures offbalance sheet arrangements specialpurpose entities activities included nonexchangetraded contracts accounted fair value ordinary course business abbvie periodically entered thirdparty agreements assignment product rights resulted abbvie becoming secondarily liable obligations abbvie previously primarily liable based upon past experience likelihood payments agreements remote abbvie periodically acquires business product rights abbvie agrees pay contingent consideration based attaining certain thresholds based occurrence certain future events note financial instruments fair value measures risk management policy company exposed foreign currency exchange rate interest rate risks related business operations company 's hedging policy attempts manage risks acceptable level based company 's judgment appropriate tradeoff risk opportunity costs company uses derivative instruments reduce exposure foreign currency exchange rates company also exposed risk earnings cash flows could adversely impacted fluctuations interest rates company periodically enters interest rate swaps based judgment manage interest costs company agrees exchange specified intervals difference fixed floating interest amounts calculated reference agreedupon notional amount derivative instruments used trading purposes manage exposure changes interest rates investment securities none company 's outstanding derivative instruments contain credit risk related contingent features collateral generally required financial instruments various abbvie foreign subsidiaries enter foreign currency forward exchange contracts manage exposures changes foreign exchange rates anticipated intercompany transactions denominated currency functional currency local entity contracts notional amounts totaling billion billion december december respectively designated cash flow hedges recorded fair value resulting gains losses reflected oci accumulated gains losses december reclassified aoci included cost products sold time products sold generally exceeding twelve months company also enters foreign currency forward exchange contracts manage exposure foreign currency denominated trade payables receivables intercompany loans contracts designated hedges recorded fair value resulting gains losses reflected net foreign exchange loss consolidated statements earnings generally offset losses gains foreign currency exposure managed december december abbvie held notional amounts billion billion respectively undesignated foreign currency forward exchange contracts company entered undesignated forward exchange contracts total notional amount billion hedge anticipated foreign currency cash outflows associated terminated proposed combination shire large portion contracts originally due mature first quarter net settled fourth quarter company realized million net foreign exchange losses associated shirerelated forward exchange contracts abbvie party interest rate hedge contracts designated fair value hedges totaling billion billion december december respectively effect hedge change fixedrate interest obligation floating rate portion debt abbvie recorded contracts fair value adjusted carrying amount fixedrate debt offsetting amount following table summarizes amounts location abbvie 's derivative instruments consolidated balance sheets fair valuederivatives asset position fair valuederivatives liability position balance sheet december millions caption balance sheet caption foreign currency forward exchange contracts hedging instruments prepaid expenses accounts payable accrued liabilities others designated hedges prepaid expenses accounts payable accrued liabilities interest rate swaps designated prepaid expenses fair value hedges longterm liabilities total derivatives certain derivatives subject netting arrangements company 's counterparties company offset derivative assets liabilities within consolidated balance sheets unrealized gainslosses effective portions derivative instruments designated cash flow hedges recognized oci million million million respectively amount hedge ineffectiveness significant years presented following table summarizes pretax amounts location consolidated statements earnings net gainslosses recognized consolidated statements earnings derivative instruments including effective portions net gainslosses reclassified aoci net earnings respectively see note amount net gainslosses reclassified aoci years ended december millions statement earnings caption foreign currency forward exchange contracts designated cash flow hedges cost products sold designated hedges net foreign exchange loss interest rate swaps designated fair value hedges interest expense net total gainloss related fair value hedges recognized interest expense net consolidated statements earnings directly offsets lossgain underlying hedged item fixedrate debt resulting net impact interest expense net periods presented fair value measures fair value hierarchy accounting standard fair value measurements consists following three levels level valuations based unadjusted quoted prices active markets identical assets company ability access level valuations based quoted prices similar instruments active markets quoted prices identical similar instruments markets active modelbased valuations significant inputs observable market level valuations using significant inputs unobservable market include use judgment company 's management assumptions market participants would use pricing asset liability following table summarizes bases used measure certain assets liabilities carried fair value recurring basis consolidated balance sheet december basis fair value measurement quoted prices significant active markets significant observable unobservable identical assets inputs inputs millions total level level level assets cash equivalents time deposits equity securities interest rate hedges foreign currency contracts total assets liabilities interest rate hedges foreign currency contracts total liabilities following table summarizes bases used measure certain assets liabilities carried fair value recurring basis consolidated balance sheet december basis fair value measurement quoted prices significant active markets significant observable unobservable identical assets inputs inputs millions total level level level assets cash equivalents time deposits equity securities foreign currency contracts total assets liabilities interest rate hedges foreign currency contracts total liabilities fair values time deposits included cash equivalents shortterm investments determined based discounted cash flow analysis reflecting quoted market rates similar instruments fair values time deposits approximate amortized cost due short maturities instruments availableforsale equity securities consists investments fair values determined using published market price per unit multiplied number units held without consideration transaction costs derivatives entered company valued using publicized spot curves interest rate hedges publicized forward curves foreign currency contracts cumulative net unrealized holding gains availableforsale equity securities totaled million million december december respectively transfers assets liabilities fair value measurement levels addition financial instruments company required recognize fair value consolidated balance sheets company certain financial instruments recognized historical cost basis fair value carrying values fair values certain financial instruments summarized table approximate book values fair values december millions assets investments liabilities shortterm borrowings current portion longterm debt lease obligations longterm debt lease obligations excluding fair value hedges following table summarizes bases used measure approximate fair values financial instruments december basis fair value measurement quoted prices significant active markets significant observable unobservable identical assets inputs inputs millions total level level level assets investments total assets liabilities shortterm borrowings current portion longterm debt lease obligations longterm debt lease obligations excluding fair value hedges total liabilities following table summarizes bases used measure approximate fair values financial instruments december basis fair value measurement quoted prices active significant markets significant identical observable unobservable assets inputs inputs millions total level level level assets investments total assets liabilities shortterm borrowings current portion longterm debt lease obligations longterm debt lease obligations excluding fair value hedges total liabilities investments consist cost method investments heldtomaturity debt securities determine fair values cost method investments company takes consideration recent transactions well financial information investee represents level basis fair value measurement fair value heldtomaturity debt securities estimated based upon quoted market prices similar debt instruments fair values shortterm current borrowings approximate carrying values due short maturities instruments fair values longterm debt excluding fair value hedges term loans determined using published market price debt instruments without consideration transaction costs represents level basis fair value measurement fair values term loans determined based discounted cash flow analysis using quoted market rates represents level basis fair value measurement counterparties financial instruments consist select major international financial institutions concentrations risk company invests excess cash time deposits money market funds diversifies concentration cash among different financial institutions company monitors concentrations credit risk associated deposits financial institutions credit exposure limits established limit concentration single issuer institution functional currency company 's venezuela operations us dollar due hyperinflationary status venezuelan economy currency restrictions enacted venezuela require approval venezuelan government exchange venezuelan bolivars vef us dollars require exchange made official exchange rate established government first quarter venezuelan government expanded number exchange mechanisms three rates exchange december official rate supplementary system administration foreign currency sicad rate approximately foreign exchange marginal system simadi rate approximately consolidated financial statements year ended december company used official rate vef per us dollar reported million net monetary assets million net revenues denominated venezuelan bolivar february venezuelan government announced plans devalue official rate vef us dollars eliminate sicad rate vef us dollars devaluation venezuelan bolivar result charge abbvie 's results operations first quarter abbvie 's net monetary assets denominated venezuelan bolivar converted rate vef us dollars december company would reported devaluation loss million abbvie 's net monetary assets denominated venezuelan bolivar converted simadi rate december company would reported devaluation loss million company predict whether devaluations venezuelan currency whether use official rate continue supported evolving facts circumstances could result significant charge abbvie 's results operations time company also continues business foreign governments certain oilexporting countries including venezuela saudi arabia experienced deterioration economic conditions due decline price oil liquidity issues certain countries may result delays collection receivables three us wholesalers accounted percent percent total net accounts receivable december december respectively substantially abbvie 's net revenues united states three wholesalers addition net governmental receivables outstanding greece portugal italy spain totaled million december million december humira adalimumab abbvie 's single largest product accounted approximately percent percent percent abbvie 's total net revenues respectively note postemployment benefits abbvie sponsors various pension postemployment benefit plans including defined benefit defined contribution termination indemnity plans cover employees worldwide addition abbvie provides medical benefits primarily eligible retirees united states puerto rico postretirement benefit plans net obligations plans reflected consolidated balance sheets december abbvie 's principal domestic defined benefit plan abbvie pension plan abbvie employees eligible participate abbott pension plan december automatically became eligible abbvie pension plan first quarter abbvie pension plan assumed obligations related assets abbvie employees abbott abbvie made voluntary contributions million million million respectively plan abbvie also made voluntary contribution million plan subsequent december benefit plan information table pertains global abbviesponsored defined benefit postemployment plans defined postemployment benefit plans plans years ended december millions projected benefit obligations beginning period service cost interest cost employee contributions plan amendments actuarial gain loss benefits paid primarily foreign currency translation adjustments end period fair value plan assets beginning period actual loss return plan assets company contributions employee contributions benefits paid primarily foreign currency translation adjustments end period funded status end period amounts recognized consolidated balance sheets noncurrent assets accounts payable accrued liabilities longterm liabilities net obligation actuarial losses net prior service cost accumulated comprehensive loss december projected benefit obligations pbo table included billion billion december respectively related international defined benefit plans number generally funded permitted local regulations benefit payments plans funded company assets abbvie considered release new mortality tables projection scales society actuaries determined improvement estimate future mortality opted change new tables determining funded status december society actuaries released improvement scale adjusted previously issued scale abbvie determined appropriate utilize determining funded status december plans reflected table accumulated benefit obligations abo billion billion december respectively plans reflected table abo exceeded plan assets december abo pbo aggregate plan assets billion billion billion respectively amounts recognized accumulated comprehensive loss comprehensive loss income defined benefit postemployment plans ' actuarial gains losses prior service costs credits yet recognized net periodic benefit cost included aoci net tax amortized net periodic benefit cost future periods following table summarizes pretax gains losses included comprehensive loss income years ended december millions defined benefit plans actuarial gain loss prior service cost amortization actuarial losses prior service costs foreign exchange gain loss total pretax gain loss recognized comprehensive income loss postemployment plans actuarial gain loss prior service cost amortization actuarial losses prior service costs total pretax gain loss recognized comprehensive income loss pretax amount actuarial loss prior service cost included aoci december expected recognized net periodic benefit cost million defined benefit plans million postemployment plans net periodic benefit cost years ended december millions defined benefit plans service cost interest cost expected return plan assets amortization actuarial losses prior service costs net periodic benefit cost postemployment plans service cost interest cost amortization actuarial gain loss prior service costs net periodic benefit cost weightedaverage assumptions used determining benefit obligations measurement date december defined benefit plans discount rate rate compensation increases postemployment plans discount rate assumptions used calculating december measurement date benefit obligations used calculation net periodic benefit cost weightedaverage assumptions used determining net periodic benefit cost years ended december defined benefit plans discount rate expected longterm rate return plan assets expected rate change compensation postemployment plans discount rate effective december abbvie elected change method uses estimate service interest cost components net periodic benefit costs abbvie pension plan primary postemployment benefit plan united states well certain international defined benefit plans postemployment benefit plans historically abbvie estimated service interest cost components expense utilizing single weightedaverage discount rate derived yield curve used measure benefit obligation beginning period late abbvie elected utilize full yield curve approach estimation components applying specific spot rates along yield curve used determination benefit obligation relevant projected cash flows abbvie elected make change provide precise measurement service interest costs improving correlation projected benefit cash flows corresponding spot yield curve rates abbvie accounted change prospectively change accounting estimate inseparable change accounting principle based current economic conditions change expected reduce abbvie 's net periodic benefit cost approximately million change effect expense affect measurement abbvie 's total benefit obligations change service cost interest cost completely offset actuarial gain loss reported purposes measuring postretirement health care obligations measurement date company assumed percent pre percent post annual rate increase per capita cost covered health care benefits rate assumed decrease gradually percent remain level thereafter purposes measuring postretirement health care costs company assumed percent pre percent post annual rate increase per capita cost covered health care benefits rate assumed decrease gradually percent remain level thereafter assumed health care cost trend rates significant effect amounts reported health care plans december percentage point change assumed health care cost trend rates would following effects one percentage point year ended december millions brackets denote reduction increase decrease service cost interest cost projected benefit obligation defined benefit pension plan assets basis fair value measurement quoted prices significant active markets significant observable unobservable identical assets inputs inputs december millions level level level equities us large capa us mid capb internationalc fixed income securities us government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real assets otherf fair value plan assets basis fair value measurement quoted prices significant active markets significant observable unobservable identical assets inputs inputs december millions level level level equities us large capa us mid capb internationalc fixed income securities us government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real assets otherf fair value plan assets mix pooled index funds actively managed equity accounts benchmarked various large cap indices b mix pooled index funds actively managed equity accounts benchmarked various mid cap indices c mix pooled index funds actively managed equity accounts benchmarked various nonus equity indices developed emerging markets securities held actively managed accounts pooled index funds mutual funds e funds global mandates flexibility allocate capital broadly across wide range asset classes strategies including limited equities fixed income commodities financial futures currencies securities objectives outperform agreed upon benchmarks specific return volatility targets f investments cash cash equivalents equities valued using quoted prices valued published market prices equities common collective trust registered investment company valued using significant observable inputs valued net asset value nav provided fund administrator nav based value underlying assets owned fund minus liabilities fixed income securities valued using significant observable inputs valued prices obtained independent financial service industryrecognized vendors absolute return funds commodities valued nav provided fund administrator following table summarizes change value plan assets measured using significant unobservable inputs level years ended december millions beginning period actual return plan assets hand end period purchases sales settlements net end period investment mix equity securities fixed income asset allocation strategies based upon achieving desired return balancing higher return volatile equity securities lower return less volatile fixed income securities investment allocations established plan generally made across range markets industry sectors capitalization sizes case fixed income securities maturities credit quality target investment allocations abbvie pension plan percent equity securities percent fixed income securities percent asset allocation strategies holdings known significant concentrations risk plan assets abbvie pension plan plans ' assets plans ' expected return plan assets assumption shown based management 's expectations longterm average rates return achieved underlying investment portfolios establishing assumption management considers historical expected returns asset classes plans invested well current economic capital market conditions expected defined benefit postemployment plan payments defined post benefit employment years ended december millions plans plans table reflects total benefit payments expected paid participants includes payments funded company assets well paid plans abbvie 's principal defined contribution plan abbvie savings plan abbvie recorded expense million million million related plan abbvie provides certain postemployment benefits primarily salary continuation arrangements qualifying employees accrues related cost service lives employees note equity stockbased compensation stockbased compensation expense million million million respectively principally classified sga periods presented remainder classified rd expenses cost products sold related tax benefit recognized million million million respectively compensation expense stockbased awards measured based fair value awards date stockbased awards granted adjusted estimated number awards expected vest forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates compensation cost stockbased awards amortized service period could shorter vesting period employee retirement eligible charge compensation expense stockbased awards granted retirementeligible employees compensation expense recognized immediately grant date employee able retain award without continuing provide service retirement eligible employees generally age least ten years service prior separation abbvie employees participated abbott 's incentive stock program abbvie incentive stock program adopted time separation facilitated assumption certain awards granted abbott 's incentive stock program authorizes postseparation grant several different forms benefits including nonqualified stock options rsas rsus performancebased rsas rsus abbvie incentive stock program million shares common stock reserved issuance respect postseparation awards participants connection separation outstanding abbott employee stock options rsas rsus previously issued abbott 's incentive stock program adjusted converted new abbott abbvie stockbased awards using formula designed preserve intrinsic value fair value awards immediately prior separation upon separation january holders abbott stock options rsas rsus generally received one abbvie stockbased award abbott stockbased award outstanding adjusted awards retained vesting schedule expiration date original awards abbvie awards granted abbott employees connection separation realized excess tax benefits associated stockbased compensation recorded additional paidin capital totaled million million million respectively presented consolidated statements cash flows outflow operating activities inflow financing activities stock options exercise price options granted least equal percent fair value date grant stock options typically contractual term years generally vest onethird increments threeyear period fair value stock options determined using blackscholes model weightedaverage grantdate fair values stock options granted respectively stockbased compensation expense attributable options years presented material following table summarizes abbvie stock option activity weighted weighted average average remaining aggregate year ended december exercise life intrinsic options thousands aggregate intrinsic value millions options price years value outstanding beginning period granted exercised lapsed outstanding end period exercisable end period aggregate intrinsic value table represents difference exercise price company 's closing share price last day trading total intrinsic value options exercised million million million respectively total fair value options vested million rsas rsus rsas rsus generally vest onethird increments three years upon vesting recipient receives one share common stock vested award abbvie grants performancebased rsas rsus selected executives key employees vesting primarily contingent upon abbvie achieving minimum return equity fair value rsas rsus including performancebased awards determined based number shares granted quoted price abbvie 's common stock date grant purposes determining compensation expense abbvie periodically evaluates whether performance goals achieved goals met compensation expense recognized previously recognized compensation expense reversed following table summarizes abbvie rsa rsu activity including performancebased awards abbvie abbott employees weighted average share grant date fair year ended december share units thousands units value outstanding beginning period granted vested lapsed outstanding end period fair market value rsas rsus vested million million million respectively december million unrecognized compensation cost related rsas rsus expected recognized expense approximately next two years cash dividends february may august november abbvie paid quarterly cash dividends per share common stock respectively declared board directors october february june september respectively dividends declared october february represented increase nearly percent approximately percent respectively previous quarterly rates per share per share respectively october company announced board directors declared increase company 's quarterly cash dividend per share per share beginning dividend payable february stockholders record january reflects increase approximately percent previous quarterly rate february may august november abbvie paid quarterly cash dividends per share common stock respectively declared board directors december february june september respectively stock repurchase program february abbvie 's board directors authorized billion stock repurchase program october abbvie 's board directors authorized new billion stock repurchase program effective immediately superseded previous authorization current stock repurchase authorization permits purchases abbvie shares time time open market private transactions management 's discretion depending company 's cash flows net debt level market conditions program time limit discontinued time march board directors authorized billion increase existing stock repurchase program anticipation executing accelerated share repurchase agreement connection acquisition pharmacyclics may abbvie entered executed billion asr morgan stanley pursuant terms asr morgan stanley made initial delivery approximately million shares abbvie 's common stock may represented approximately percent total shares expected delivered asr morgan stanley subsequently delivered additional million shares abbvie 's common stock abbvie final settlement asr abbvie recorded aggregate billion purchase price reduction common stock held treasury consolidated balance sheet december addition asr abbvie repurchased approximately million shares million shares million shares billion million million respectively open market abbvie settled million open market purchases shares repurchased programs recorded acquisition cost including related expenses available general corporate purposes abbvie 's remaining share repurchase authorization billion december accumulated comprehensive loss following table summarizes changes component aoci net tax unrealized gains foreign pension losses currency post marketable translation employment equity hedging millions brackets denote losses adjustments benefits securities activities total balance december comprehensive income loss reclassifications net losses reclassified accumulated comprehensive loss net currentperiod comprehensive income loss separationrelated adjustments balance december comprehensive loss income reclassifications net losses reclassified accumulated comprehensive loss net currentperiod comprehensive loss income balance december comprehensive income reclassifications net losses gains reclassified accumulated comprehensive loss net currentperiod comprehensive loss income balance december comprehensive loss includes foreign currency translation adjustments totaling loss billion principally driven impact substantial weakening euro translation company 's eurodenominated assets ii weakening foreign currencies combination increased concentration cash denominated foreign currencies accumulated anticipation terminated proposed combination shire plc comprehensive loss includes foreign currency translation adjustments totaling loss million principally driven impact continued weakening euro translation company 's eurodenominated assets table presents impact abbvie 's consolidated statements earnings significant amounts reclassified component accumulated comprehensive loss years ended december millions brackets denote gains pension postemployment benefits amortization actuarial losses othera less tax benefit total reclassifications net tax hedging activities gains losses designated cash flow hedgesb less tax expense benefit total reclassifications net tax amounts included computation net periodic benefit cost see note b amounts included cost products sold see note addition common stock abbvie 's authorized capital includes million shares preferred stock par value december shares preferred stock issued outstanding note income taxes earnings income tax expense years ended december millions domestic foreign total earnings income tax expense domestic loss income taxes driven transaction financingrelated costs associated terminated proposed combination shire refer note information income tax expense years ended december millions current domestic foreign total current taxes deferred domestic foreign total deferred taxes total income tax expense effective tax rate reconciliation years ended december statutory tax rate state taxes net federal benefit effect foreign operations us tax credits branded prescription drug fee valuation allowances net effective tax rate effective tax rate fluctuates year year due allocation company 's taxable earnings among jurisdictions well certain discrete factors events year including acquisitions collaborations effective tax rates differed statutory tax rate principally due benefit foreign operations reflects impact lower income tax rates locations outside united states tax exemptions incentives puerto rico foreign tax jurisdictions business development activities together cost repatriation decisions effective tax rates periods also reflected benefit us tax credits principally related research development credits orphan drug tax credit puerto rico excise tax credits research development credits due legislation enacted fourth quarter year retroactively extended credit puerto rico excise tax credits relate legislation enacted puerto rico assesses excise tax beginning certain products manufactured puerto rico tax levied gross inventory purchases entities puerto rico included cost products sold consolidated statements earnings majority tax creditable us income tax purposes effective income tax rate included tax benefit million reduction state valuation allowances effective tax rate included additional expenses million related branded prescription drug fee nondeductible state valuation allowances million july internal revenue service issued final rules regulations branded prescription drug fee annual nontaxdeductible fee payable federal government affordable care act based allocation company 's market share branded prescription drugs sold certain government programs prior year final rules accelerated expense recognition criteria fee obligation year fee paid year market share used allocate fee determined change required abbvie industry participants recognize additional year expense effective income tax rate reflects income tax expenses relating current earnings outside united states deemed indefinitely reinvested deferred tax assets liabilities december millions deferred tax assets compensation employee benefits accruals reserves chargebacks rebates deferred revenue depreciation net operating losses credit carryforwards total deferred tax assets valuation allowances total net deferred tax assets deferred tax liabilities excess book basis tax basis intangible assets excess book basis tax basis investments total deferred tax liabilities net deferred tax liabilities assets increases deferred tax liabilities primarily due acquisition pharmacyclics abbvie recorded excess book basis tax basis intangible assets investments gross federal net operating loss tax credit carryforwards december million million respectively available use gross state net operating loss tax credit carryforwards december billion million respectively state tax carryforwards expire december foreign net operating loss carryforwards million foreign net operating loss carryforwards million expire remaining expiration period december company valuation allowances million million respectively principally related state net operating losses credit carryforwards expected realized deferred income taxes provided approximately billion undistributed earnings foreign subsidiaries earnings indefinitely reinvested continued use foreign operations due complexities tax laws assumptions would made practicable estimate amount income taxes would due earnings distributed unrecognized tax benefits years ended december millions balance january increase due current year tax positions increase due prior year tax positions decrease due prior year tax positions lapse statutes limitations separationrelated adjustments balance december abbvie abbott entered tax sharing agreement effective date separation provides abbott liable indemnified abbvie income tax liabilities periods prior separation abbvie responsible unrecognized tax benefits related interest penalties periods separation instances existing entity transferred abbvie upon separation table reflects reduction billion relating tax periods prior separation abbott primary obligor however us treasury regulations member consolidated group severally liable us federal income tax liability member consolidated group accordingly respect periods abbvie included abbott 's consolidated group abbvie could liable us government us federal income tax liability incurred consolidated group extent discharged member however liability imposed abbvie would entitled indemnified abbott pursuant tax sharing agreement recognized net amount potential tax benefits would impact company 's effective tax rate million million respectively unrecognized tax benefits recorded table december abbvie would indemnified approximately million increase due prior year tax positions table includes amounts relating federal state international items well prior positions acquired business development activities year uncertain tax positions generally included longterm liability consolidated balance sheets abbvie recognizes interest penalties related income tax matters income tax expense abbvie recognized gross income tax expense million million million respectively interest penalties related income tax matters december abbvie million million million accrued payment gross interest penalties company routinely audited tax authorities significant jurisdictions number audits currently underway reasonably possible next twelve months uncertain tax positions may settled could result decrease gross amount unrecognized tax benefits due potential resolution federal state foreign examinations expiration various statutes limitation company 's gross unrecognized tax benefits balance may change within next twelve months million significant federal state local international matters concluded years company believes adequate provision made income tax uncertainties note legal proceedings contingencies abbvie subject contingencies various claims legal proceedings investigations regarding product liability intellectual property commercial securities matters arise normal course business loss contingency provisions recorded probable losses management 's best estimate loss best estimate made minimum loss contingency amount within probable range recorded recorded accrual balance litigation december million december significant initiation new legal proceedings change status existing proceedings may result change estimated loss accrued abbvie feasible predict outcome proceedings exposures certainty management believes ultimate disposition material adverse effect abbvie 's consolidated financial position results operations cash flows subject certain exceptions specified separation agreement abbott abbvie abbvie assumed liability control pending threatened legal matters related business including liabilities claims legal proceedings related products part business discontinued prior distribution well assumed retained liabilities indemnify abbott liability arising resulting assumed legal matters several pending lawsuits filed unimed pharmaceuticals inc solvay pharmaceuticals inc company abbott acquired february known abbvie products llc others consolidated pretrial purposes united states district court northern district georgia multidistrict litigation mdl rules androgel antitrust litigation mdl cases brought private plaintiffs federal trade commission ftc generally allege solvay 's patent litigation involving androgel sham litigation patent litigation settlement agreement related agreements three generic companies violate federal state antitrust laws state consumer protection unjust enrichment laws plaintiffs generally seek monetary damages andor injunctive relief attorneys ' fees mdl includes four individual plaintiff lawsuits b six purported class actions c federal trade commission v watson pharmaceuticals inc et al following district court 's dismissal plaintiffs ' claims appellate proceedings led reinstatement claims regarding patent litigation settlement proceeding discovery district court attorney general state alaska served abbvie civil investigative demand primarily seeking documents abbvie produced lawsuits november glaxosmithkline plc gsk filed lawsuit abbott united states district court northern district california alleging abbott violated federal antitrust various state laws connection norvir repricing march jury found abbott violate antitrust laws breached license agreement gsk january united states court appeals ninth circuit reversed verdict remanded case new trial due alleged improper exclusion potential juror case returned district court california gsk dismissed federal antitrust claims case transferred april united states district court middle district north carolina pretrial proceedings pending abbvie assumed liability control proceeding connection separation abbott lawsuits pending abbvie others generally alleging patent litigation settlement involving niaspan entered kos pharmaceuticals inc company acquired abbott presently subsidiary abbvie generic company violates federal state antitrust laws state unfair deceptive trade practices unjust enrichment laws plaintiffs generally seek monetary damages andor injunctive relief attorneys ' fees lawsuits consist three individual plaintiff lawsuits two consolidated purported class actions one brought three named direct purchasers niaspan brought ten named endpayor purchasers niaspan cases consolidated pretrial proceedings united states district court eastern district pennsylvania mdl rules niaspan antitrust litigation mdl office attorney general state alaska served abbvie civil investigative demand primarily seeking documents abbvie produced lawsuit september ftc filed suit united states district court eastern district pennsylvania abbvie others alleging patent litigation two generic companies regarding androgel sham litigation patent litigation settlement one generic companies violates federal antitrust laws ftc 's complaint seeks monetary damages injunctive relief may court dismissed ftc 's claim regarding patent litigation settlement office attorney general state alaska served abbvie civil investigative demand primarily seeking documents abbvie produced lawsuit march state louisiana filed lawsuit state louisiana v fournier industrie et sante et al abbvie abbott affiliated abbott entities louisiana state court plaintiff alleges patent applications patent litigation filed alleged conduct early 's related drug tricor violated louisiana state antitrust unfair trade practices laws lawsuit seeks monetary damages attorneys ' fees august court dismissed case timebarred state 's appeal dismissal pending august putative class action lawsuit sidney hillman health center rochester et al v abbvie inc et al filed abbvie united states district court northern district illinois three healthcare benefit providers alleging violations federal racketeer influenced corrupt organizations rico statutes state deceptive business practice unjust enrichment laws connection reimbursements certain uses depakote plaintiffs seek monetary damages andor equitable relief attorneys ' fees november putative class action lawsuit medical mutual ohio v abbvie inc et al filed several manufacturers testosterone replacement therapies trts including abbvie united states district court northern district illinois behalf insurance companies health benefit providers third party payors paid trts including androgel claims asserted include violations federal rico act state consumer fraud deceptive trade practices laws complaint seeks monetary damages injunctive relief similar lawsuit allied services division welfare fund v abbvie inc et al filed court october behalf putative class members putative class consumers product liability cases pending plaintiffs generally allege abbvie manufacturers trts adequately warn risks certain injuries primarily heart attacks strokes blood clots approximately claims consolidated pretrial purposes united states district court northern district illinois mdl rules testosterone replacement therapy products liability litigation mdl approximately claims pending various state courts plaintiffs seek compensatory punitive damages product liability cases pending plaintiffs generally allege abbvie adequately warn risk certain injuries primarily various birth defects arising use depakote ninety percent approximately claims pending united states district court southern district illinois rest pending various federal state courts plaintiffs seek compensatory punitive damages november five individuals filed putative class action lawsuit behalf purchasers sellers certain shire securities june october abbvie chief executive officer united states district court northern district illinois alleging defendants made andor responsible material misstatements violation federal securities laws connection abbvie 's proposed transaction shire complaint seeks monetary damages injunctive relief december shareholder derivative lawsuit plumbers steamfitters local pension plans v jp morgan securities llc et al filed delaware chancery court alleging abbvie 's directors breached fiduciary duties connection approval termination abbvie 's proposed transaction shire lawsuit seeks monetary damages abbvie among relief note segment geographic area information abbvie operates one business segmentpharmaceutical products substantially abbvie 's net revenues united states three wholesalers outside united states products sold primarily health care providers distributors depending market served following tables detail abbvie 's worldwide net revenues years ended december millions humira imbruvica viekira creon synagis lupron synthroid kaletra androgel sevoflurane duodopa dyslipidemia products total net revenues net revenues external customers geographic area based product shipment destination follows years ended december millions united states germany united kingdom spain japan france canada italy brazil netherlands countries total net revenues longlived assets include net property equipment billion billion december billion billion respectively located united states puerto rico million million respectively located europe note quarterly financial data unaudited millions except per share data first quarter net revenues gross margin net earningsa basic earnings per share diluted earnings per share cash dividends declared per common share second quarter net revenues gross margin net earningsb basic earnings per share diluted earnings per share cash dividends declared per common share third quarter net revenues gross margin net earningsc basic earnings per share diluted earnings per share cash dividends declared per common share fourth quarter net revenuesd gross margind net earnings losse basic earnings loss per share f diluted earnings loss per share f cash dividends declared per common share results first quarter included aftertax foreign exchange losses million related liquidation remaining foreign currency positions related terminated proposed combination shire million aftertax charge result entering exclusive worldwide license agreement cn aftertax costs million incurred connection acquisition pharmacyclics b second quarter results included aftertax costs totaling million incurred connection acquisition integration pharmacyclics second quarter results included aftertax charge million related regulatory milestone made collaboration partner regulatory milestones related company 's hcv program c results third quarter included million aftertax charge related purchase rare pediatric disease prv united therapeutics corporation aftertax costs totaling million incurred connection acquisition integration pharmacyclics million aftertax charge due achievement development milestone global collaboration infinity third quarter results included million aftertax charge result entering global collaboration infinity million aftertax charge related research development collaboration agreement calico transaction financingrelated costs aggregating million aftertax incurred connection terminated proposed combination shire refer note information relating termination proposed combination shire collaborations calico infinity net revenues gross margin included milestone revenue million collaboration partner related company 's oncology program net revenues gross margin include royalty income million relating prior periods result settlement licensing arrangement e fourth quarter results included aftertax costs totaling million incurred connection acquisition integration pharmacyclics aftertax charges million increase company 's litigation reserves results fourth quarter included aftertax transaction financingrelated costs incurred connection terminated proposed combination shire aggregating billion million aftertax charge related research development collaboration agreement calico f basic loss per share fourth quarter calculated treasurystock method dilutive approximately million common shares excluded computation diluted loss per share assuming dilution effect would antidilutive report independent registered public accounting firm board directors shareholders abbvie inc audited accompanying consolidated balance sheets abbvie inc subsidiaries december related consolidated statements earnings comprehensive income equity cash flows three years period ended december financial statements responsibility company 's management responsibility express opinion financial statements based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position abbvie inc subsidiaries december consolidated results operations cash flows three years period ended december conformity us generally accepted accounting principles also audited accordance standards public company accounting oversight board united states abbvie inc subsidiaries ' internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework report dated february expressed unqualified opinion thereon ernst young llp chicago illinois february item changes disagreements accountants accounting financial disclosure none item controls procedures disclosure controls procedures evaluation disclosure controls procedures chief executive officer richard gonzalez chief financial officer william j chase evaluated effectiveness abbvie 's disclosure controls procedures end period covered report concluded abbvie 's disclosure controls procedures effective ensure information abbvie required disclose reports files submits securities exchange commission securities exchange act recorded processed summarized reported within time periods specified commission 's rules forms ensure information required disclosed abbvie reports files submits securities exchange act accumulated communicated abbvie 's management including principal executive officer principal financial officer appropriate allow timely decisions regarding required disclosure internal control financial reporting management 's annual report internal control financial reporting management 's report internal control financial reporting included hereof report abbvie 's independent registered public accounting firm related assessment effectiveness internal control financial reporting included hereof changes internal control financial reporting part separation abbott abbvie began phased global implementation new enterprise resource planning system related technology infrastructure transaction processing services replace information technology infrastructure transactional services provided abbvie abbott various transition services agreements initiatives completed included modifications design operation controls financial reporting abbvie reviewed controls design effectiveness prior implementation phase changes abbvie 's internal control financial reporting defined rule af securities exchange act materially affected reasonably likely materially affect abbvie 's internal control financial reporting quarter ended december inherent limitations effectiveness controls abbvie 's management including chief executive officer chief financial officer expect abbvie 's disclosure controls internal control financial reporting prevent detect errors fraud control system matter well designed operated provide reasonable absolute assurance control system 's objectives met design control system must reflect fact resource constraints benefits controls must considered relative costs inherent limitations control systems evaluation controls provide absolute assurance misstatements due error fraud occur control issues instances fraud detected inherent limitations include realities judgments decisionmaking faulty breakdowns occur simple error mistake controls also circumvented individual acts persons collusion two people management override controls design system controls based part certain assumptions likelihood future events assurance design succeed achieving stated goals potential future conditions projections evaluation controls effectiveness future periods subject risks time controls may become inadequate changes conditions deterioration degree compliance policies procedures item b information none management 's report internal control financial reporting management abbvie responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act abbvie 's internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states however internal control systems matter well designed inherent limitations therefore even systems determined effective provide reasonable assurance respect financial statement preparation reporting management assessed effectiveness abbvie 's internal control financial reporting december making assessment management used criteria set forth committee sponsoring organizations treadway commission coso internal control integrated framework framework based assessment management concluded abbvie maintained effective internal control financial reporting december based coso criteria may abbvie acquired pharmacyclics inc pharmacyclics represents material change internal control financial reporting since management 's last assessment effectiveness management excluded pharmacyclics assessment conclusion effectiveness internal control financial reporting december abbvie 's consolidated balance sheet december included billion total assets excluding goodwill intangible assets included management 's assessment internal controls financial reporting related pharmacyclics addition abbvie 's consolidated statement net earnings included million net revenues reflected net loss million related pharmacyclics effectiveness abbvie 's internal control financial reporting december audited ernst young llp independent registered public accounting firm stated attestation report appearing hereof expresses unqualified opinion effectiveness abbvie 's internal control financial reporting december report independent registered public accounting firm board directors shareholders abbvie inc audited abbvie inc subsidiaries ' internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework coso criteria abbvie inc subsidiaries ' management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinion company 's internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion company 's internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate indicated accompanying management 's report internal control financial reporting management 's assessment conclusion effectiveness internal control financial reporting include internal controls pharmacyclics inc acquired may included consolidated financial statements abbvie inc subsidiaries constituted billion total assets excluding goodwill intangible assets included management 's assessment conclusions effectiveness internal control financial reporting december million million revenues net loss respectively year ended audit internal control financial reporting abbvie inc subsidiaries also include evaluation internal control financial reporting pharmacyclics inc opinion abbvie inc subsidiaries ' maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated balance sheets december related consolidated statements earnings comprehensive income equity cash flows three years period ended december abbvie inc subsidiaries report dated february expressed unqualified opinion thereon ernst young llp chicago illinois february part iii item directors executive officers corporate governance incorporated herein reference information concerning director nominees board directors committeescommittees board directors section beneficial ownership reporting compliance procedure recommendation nomination directors transaction business annual meeting included abbvie inc proxy statement definitive proxy statement filed march also incorporated herein reference text found caption executive officers registrant pages hereof abbvie 's code business conduct requires business activities conducted compliance applicable laws regulations ethical principles values directors officers employees abbvie required read understand abide requirements code business conduct applicable abbvie 's code business conduct available corporate governance section abbvie 's investor relations website wwwabbvieinvestorcom waiver code business conduct directors executive officers may made abbvie 's audit committee abbvie disclose amendment waiver provision code conduct principal executive officer principal financial officer principal accounting officer controller persons performing similar functions website within four business days following date amendment waiver addition abbvie disclose waiver code business conduct executive officers directors website abbvie chief ethics compliance officer reports chief executive officer public policy committee chief ethics compliance officer responsible overseeing administering monitoring abbvie 's compliance program item executive compensation material included proxy statement headings director compensation executive compensation compensation committee report incorporated herein reference definitive proxy statement filed march item security ownership certain beneficial owners management related stockholder matters equity compensation plan information following table presents information december abbvie 's equity compensation plans abbvie common stock authorized issuance c number securities remaining available number b future securities weighted issuance average equity issued upon exercise compensation exercise price plans outstanding outstanding excluding options options securities warrants warrants reflected plan category rights rights column equity compensation plans approved security holders equity compensation plans approved security holders total includes shares issuable abbvie 's incentive stock program pursuant awards granted abbott adjusted abbvie awards connection abbvie 's separation abbott weightedaverage exercise price include outstanding restricted stock units restricted stock awards exercise price b information concerning security ownership incorporated herein reference material heading securities ownership securities ownership executive officers directors proxy statement definitive proxy statement filed march item certain relationships related transactions director independence material included proxy statement headings board directors committees corporate governance materials procedures approval related person transactions incorporated herein reference definitive proxy statement filed march item principal accounting fees services material included proxy statement headings audit fees nonaudit fees policy audit committee preapproval audit permissible nonaudit services independent registered public accounting firm incorporated herein reference definitive proxy statement filed march part iv item